Source Name	Characteristics[organism]	Characteristics[organism part]	Characteristics[pool]	Characteristics[age]	Characteristics[ancestry category]	Characteristics[cell type]	characteristics[developmental stage]	Characteristics[Compound]	Characteristics[phenotype]	Characteristics[depletion]	Characteristics[cell line]	Characteristics[sex]	Characteristics[disease]	Characteristics[individual]	assay name	Technology Type	comment[fraction identifier]	comment[label]	comment[data file]	comment[file uri]	comment[instrument]	comment[cleavage agent details]	comment[modification parameters]	comment[modification parameters]	comment[modification parameters]	comment[modification parameters]	comment[dissociation method]	comment[collision energy]	comment[fragment mass tolerance]	comment[precursor mass tolerance]	Material Type	Factor value[Compound]	Factor value[phenotype]
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 1	proteomic profiling by mass spectrometer	1	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 1	proteomic profiling by mass spectrometer	1	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 1	proteomic profiling by mass spectrometer	1	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 1	proteomic profiling by mass spectrometer	1	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 1	proteomic profiling by mass spectrometer	1	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 1	proteomic profiling by mass spectrometer	1	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 1	proteomic profiling by mass spectrometer	1	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 1	proteomic profiling by mass spectrometer	1	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 1	proteomic profiling by mass spectrometer	1	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 1	proteomic profiling by mass spectrometer	1	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 2	proteomic profiling by mass spectrometer	2	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 2	proteomic profiling by mass spectrometer	2	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 2	proteomic profiling by mass spectrometer	2	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 2	proteomic profiling by mass spectrometer	2	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 2	proteomic profiling by mass spectrometer	2	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 2	proteomic profiling by mass spectrometer	2	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 2	proteomic profiling by mass spectrometer	2	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 2	proteomic profiling by mass spectrometer	2	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 2	proteomic profiling by mass spectrometer	2	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 2	proteomic profiling by mass spectrometer	2	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 3	proteomic profiling by mass spectrometer	3	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 3	proteomic profiling by mass spectrometer	3	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 3	proteomic profiling by mass spectrometer	3	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 3	proteomic profiling by mass spectrometer	3	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 3	proteomic profiling by mass spectrometer	3	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 3	proteomic profiling by mass spectrometer	3	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 3	proteomic profiling by mass spectrometer	3	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 3	proteomic profiling by mass spectrometer	3	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 3	proteomic profiling by mass spectrometer	3	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 3	proteomic profiling by mass spectrometer	3	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 4	proteomic profiling by mass spectrometer	4	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 4	proteomic profiling by mass spectrometer	4	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 4	proteomic profiling by mass spectrometer	4	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 4	proteomic profiling by mass spectrometer	4	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 4	proteomic profiling by mass spectrometer	4	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 4	proteomic profiling by mass spectrometer	4	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 4	proteomic profiling by mass spectrometer	4	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 4	proteomic profiling by mass spectrometer	4	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 4	proteomic profiling by mass spectrometer	4	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 4	proteomic profiling by mass spectrometer	4	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 5	proteomic profiling by mass spectrometer	5	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 5	proteomic profiling by mass spectrometer	5	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 5	proteomic profiling by mass spectrometer	5	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 5	proteomic profiling by mass spectrometer	5	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 5	proteomic profiling by mass spectrometer	5	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 5	proteomic profiling by mass spectrometer	5	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 5	proteomic profiling by mass spectrometer	5	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 5	proteomic profiling by mass spectrometer	5	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 5	proteomic profiling by mass spectrometer	5	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 5	proteomic profiling by mass spectrometer	5	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 6	proteomic profiling by mass spectrometer	6	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 6	proteomic profiling by mass spectrometer	6	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 6	proteomic profiling by mass spectrometer	6	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 6	proteomic profiling by mass spectrometer	6	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 6	proteomic profiling by mass spectrometer	6	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 6	proteomic profiling by mass spectrometer	6	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 6	proteomic profiling by mass spectrometer	6	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 6	proteomic profiling by mass spectrometer	6	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 6	proteomic profiling by mass spectrometer	6	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 6	proteomic profiling by mass spectrometer	6	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 7	proteomic profiling by mass spectrometer	7	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 7	proteomic profiling by mass spectrometer	7	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 7	proteomic profiling by mass spectrometer	7	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 7	proteomic profiling by mass spectrometer	7	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 7	proteomic profiling by mass spectrometer	7	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 7	proteomic profiling by mass spectrometer	7	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 7	proteomic profiling by mass spectrometer	7	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 7	proteomic profiling by mass spectrometer	7	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 7	proteomic profiling by mass spectrometer	7	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 7	proteomic profiling by mass spectrometer	7	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 8	proteomic profiling by mass spectrometer	8	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 8	proteomic profiling by mass spectrometer	8	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 8	proteomic profiling by mass spectrometer	8	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 8	proteomic profiling by mass spectrometer	8	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 8	proteomic profiling by mass spectrometer	8	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 8	proteomic profiling by mass spectrometer	8	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 8	proteomic profiling by mass spectrometer	8	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 8	proteomic profiling by mass spectrometer	8	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 8	proteomic profiling by mass spectrometer	8	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 8	proteomic profiling by mass spectrometer	8	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 9	proteomic profiling by mass spectrometer	9	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 9	proteomic profiling by mass spectrometer	9	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 9	proteomic profiling by mass spectrometer	9	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 9	proteomic profiling by mass spectrometer	9	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 9	proteomic profiling by mass spectrometer	9	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 9	proteomic profiling by mass spectrometer	9	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 9	proteomic profiling by mass spectrometer	9	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 9	proteomic profiling by mass spectrometer	9	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 9	proteomic profiling by mass spectrometer	9	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 9	proteomic profiling by mass spectrometer	9	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 10	proteomic profiling by mass spectrometer	10	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 10	proteomic profiling by mass spectrometer	10	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 10	proteomic profiling by mass spectrometer	10	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 10	proteomic profiling by mass spectrometer	10	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 10	proteomic profiling by mass spectrometer	10	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 10	proteomic profiling by mass spectrometer	10	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 10	proteomic profiling by mass spectrometer	10	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 10	proteomic profiling by mass spectrometer	10	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 10	proteomic profiling by mass spectrometer	10	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 10	proteomic profiling by mass spectrometer	10	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 11	proteomic profiling by mass spectrometer	11	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 11	proteomic profiling by mass spectrometer	11	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 11	proteomic profiling by mass spectrometer	11	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 11	proteomic profiling by mass spectrometer	11	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 11	proteomic profiling by mass spectrometer	11	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 11	proteomic profiling by mass spectrometer	11	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 11	proteomic profiling by mass spectrometer	11	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 11	proteomic profiling by mass spectrometer	11	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 11	proteomic profiling by mass spectrometer	11	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 11	proteomic profiling by mass spectrometer	11	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 12	proteomic profiling by mass spectrometer	12	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 12	proteomic profiling by mass spectrometer	12	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 12	proteomic profiling by mass spectrometer	12	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 12	proteomic profiling by mass spectrometer	12	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 12	proteomic profiling by mass spectrometer	12	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 12	proteomic profiling by mass spectrometer	12	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 12	proteomic profiling by mass spectrometer	12	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 12	proteomic profiling by mass spectrometer	12	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 12	proteomic profiling by mass spectrometer	12	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 12	proteomic profiling by mass spectrometer	12	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 13	proteomic profiling by mass spectrometer	13	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 13	proteomic profiling by mass spectrometer	13	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 13	proteomic profiling by mass spectrometer	13	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 13	proteomic profiling by mass spectrometer	13	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 13	proteomic profiling by mass spectrometer	13	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 13	proteomic profiling by mass spectrometer	13	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 13	proteomic profiling by mass spectrometer	13	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 13	proteomic profiling by mass spectrometer	13	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 13	proteomic profiling by mass spectrometer	13	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 13	proteomic profiling by mass spectrometer	13	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 14	proteomic profiling by mass spectrometer	14	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 14	proteomic profiling by mass spectrometer	14	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 14	proteomic profiling by mass spectrometer	14	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 14	proteomic profiling by mass spectrometer	14	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 14	proteomic profiling by mass spectrometer	14	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 14	proteomic profiling by mass spectrometer	14	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 14	proteomic profiling by mass spectrometer	14	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 14	proteomic profiling by mass spectrometer	14	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 14	proteomic profiling by mass spectrometer	14	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 14	proteomic profiling by mass spectrometer	14	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 15	proteomic profiling by mass spectrometer	15	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 15	proteomic profiling by mass spectrometer	15	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 15	proteomic profiling by mass spectrometer	15	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 15	proteomic profiling by mass spectrometer	15	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 15	proteomic profiling by mass spectrometer	15	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 15	proteomic profiling by mass spectrometer	15	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 15	proteomic profiling by mass spectrometer	15	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 15	proteomic profiling by mass spectrometer	15	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 15	proteomic profiling by mass spectrometer	15	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 15	proteomic profiling by mass spectrometer	15	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 16	proteomic profiling by mass spectrometer	16	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 16	proteomic profiling by mass spectrometer	16	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 16	proteomic profiling by mass spectrometer	16	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 16	proteomic profiling by mass spectrometer	16	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 16	proteomic profiling by mass spectrometer	16	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 16	proteomic profiling by mass spectrometer	16	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 16	proteomic profiling by mass spectrometer	16	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 16	proteomic profiling by mass spectrometer	16	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 16	proteomic profiling by mass spectrometer	16	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 16	proteomic profiling by mass spectrometer	16	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 17	proteomic profiling by mass spectrometer	17	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 17	proteomic profiling by mass spectrometer	17	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 17	proteomic profiling by mass spectrometer	17	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 17	proteomic profiling by mass spectrometer	17	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 17	proteomic profiling by mass spectrometer	17	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 17	proteomic profiling by mass spectrometer	17	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 17	proteomic profiling by mass spectrometer	17	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 17	proteomic profiling by mass spectrometer	17	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 17	proteomic profiling by mass spectrometer	17	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 17	proteomic profiling by mass spectrometer	17	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 18	proteomic profiling by mass spectrometer	18	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 18	proteomic profiling by mass spectrometer	18	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 18	proteomic profiling by mass spectrometer	18	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 18	proteomic profiling by mass spectrometer	18	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 18	proteomic profiling by mass spectrometer	18	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 18	proteomic profiling by mass spectrometer	18	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 18	proteomic profiling by mass spectrometer	18	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 18	proteomic profiling by mass spectrometer	18	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 18	proteomic profiling by mass spectrometer	18	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 18	proteomic profiling by mass spectrometer	18	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 19	proteomic profiling by mass spectrometer	19	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 19	proteomic profiling by mass spectrometer	19	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 19	proteomic profiling by mass spectrometer	19	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 19	proteomic profiling by mass spectrometer	19	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 19	proteomic profiling by mass spectrometer	19	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 19	proteomic profiling by mass spectrometer	19	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 19	proteomic profiling by mass spectrometer	19	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 19	proteomic profiling by mass spectrometer	19	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 19	proteomic profiling by mass spectrometer	19	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 19	proteomic profiling by mass spectrometer	19	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 20	proteomic profiling by mass spectrometer	20	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 20	proteomic profiling by mass spectrometer	20	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 20	proteomic profiling by mass spectrometer	20	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 20	proteomic profiling by mass spectrometer	20	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 20	proteomic profiling by mass spectrometer	20	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 20	proteomic profiling by mass spectrometer	20	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 20	proteomic profiling by mass spectrometer	20	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 20	proteomic profiling by mass spectrometer	20	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 20	proteomic profiling by mass spectrometer	20	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 20	proteomic profiling by mass spectrometer	20	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 21	proteomic profiling by mass spectrometer	21	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 21	proteomic profiling by mass spectrometer	21	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 21	proteomic profiling by mass spectrometer	21	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 21	proteomic profiling by mass spectrometer	21	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 21	proteomic profiling by mass spectrometer	21	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 21	proteomic profiling by mass spectrometer	21	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 21	proteomic profiling by mass spectrometer	21	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 21	proteomic profiling by mass spectrometer	21	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 21	proteomic profiling by mass spectrometer	21	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 21	proteomic profiling by mass spectrometer	21	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 22	proteomic profiling by mass spectrometer	22	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 22	proteomic profiling by mass spectrometer	22	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 22	proteomic profiling by mass spectrometer	22	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 22	proteomic profiling by mass spectrometer	22	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 22	proteomic profiling by mass spectrometer	22	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 22	proteomic profiling by mass spectrometer	22	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 22	proteomic profiling by mass spectrometer	22	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 22	proteomic profiling by mass spectrometer	22	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 22	proteomic profiling by mass spectrometer	22	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 22	proteomic profiling by mass spectrometer	22	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 23	proteomic profiling by mass spectrometer	23	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 23	proteomic profiling by mass spectrometer	23	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 23	proteomic profiling by mass spectrometer	23	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 23	proteomic profiling by mass spectrometer	23	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 23	proteomic profiling by mass spectrometer	23	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 23	proteomic profiling by mass spectrometer	23	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 23	proteomic profiling by mass spectrometer	23	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 23	proteomic profiling by mass spectrometer	23	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 23	proteomic profiling by mass spectrometer	23	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 23	proteomic profiling by mass spectrometer	23	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 24	proteomic profiling by mass spectrometer	24	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 24	proteomic profiling by mass spectrometer	24	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 24	proteomic profiling by mass spectrometer	24	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 24	proteomic profiling by mass spectrometer	24	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 24	proteomic profiling by mass spectrometer	24	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 24	proteomic profiling by mass spectrometer	24	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 24	proteomic profiling by mass spectrometer	24	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 24	proteomic profiling by mass spectrometer	24	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 24	proteomic profiling by mass spectrometer	24	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 24	proteomic profiling by mass spectrometer	24	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 25	proteomic profiling by mass spectrometer	25	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 25	proteomic profiling by mass spectrometer	25	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 25	proteomic profiling by mass spectrometer	25	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 25	proteomic profiling by mass spectrometer	25	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 25	proteomic profiling by mass spectrometer	25	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 25	proteomic profiling by mass spectrometer	25	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 25	proteomic profiling by mass spectrometer	25	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 25	proteomic profiling by mass spectrometer	25	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 25	proteomic profiling by mass spectrometer	25	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 25	proteomic profiling by mass spectrometer	25	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 26	proteomic profiling by mass spectrometer	26	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 26	proteomic profiling by mass spectrometer	26	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 26	proteomic profiling by mass spectrometer	26	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 26	proteomic profiling by mass spectrometer	26	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 26	proteomic profiling by mass spectrometer	26	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 26	proteomic profiling by mass spectrometer	26	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 26	proteomic profiling by mass spectrometer	26	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 26	proteomic profiling by mass spectrometer	26	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 26	proteomic profiling by mass spectrometer	26	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 26	proteomic profiling by mass spectrometer	26	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 27	proteomic profiling by mass spectrometer	27	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 27	proteomic profiling by mass spectrometer	27	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 27	proteomic profiling by mass spectrometer	27	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 27	proteomic profiling by mass spectrometer	27	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 27	proteomic profiling by mass spectrometer	27	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 27	proteomic profiling by mass spectrometer	27	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 27	proteomic profiling by mass spectrometer	27	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 27	proteomic profiling by mass spectrometer	27	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 27	proteomic profiling by mass spectrometer	27	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 27	proteomic profiling by mass spectrometer	27	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 28	proteomic profiling by mass spectrometer	28	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 28	proteomic profiling by mass spectrometer	28	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 28	proteomic profiling by mass spectrometer	28	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 28	proteomic profiling by mass spectrometer	28	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 28	proteomic profiling by mass spectrometer	28	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 28	proteomic profiling by mass spectrometer	28	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 28	proteomic profiling by mass spectrometer	28	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 28	proteomic profiling by mass spectrometer	28	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 28	proteomic profiling by mass spectrometer	28	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 28	proteomic profiling by mass spectrometer	28	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 29	proteomic profiling by mass spectrometer	29	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 29	proteomic profiling by mass spectrometer	29	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 29	proteomic profiling by mass spectrometer	29	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 29	proteomic profiling by mass spectrometer	29	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 29	proteomic profiling by mass spectrometer	29	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 29	proteomic profiling by mass spectrometer	29	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 29	proteomic profiling by mass spectrometer	29	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 29	proteomic profiling by mass spectrometer	29	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 29	proteomic profiling by mass spectrometer	29	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 29	proteomic profiling by mass spectrometer	29	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 30	proteomic profiling by mass spectrometer	30	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 30	proteomic profiling by mass spectrometer	30	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 30	proteomic profiling by mass spectrometer	30	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 30	proteomic profiling by mass spectrometer	30	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 30	proteomic profiling by mass spectrometer	30	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 30	proteomic profiling by mass spectrometer	30	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 30	proteomic profiling by mass spectrometer	30	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 30	proteomic profiling by mass spectrometer	30	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 30	proteomic profiling by mass spectrometer	30	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 30	proteomic profiling by mass spectrometer	30	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 31	proteomic profiling by mass spectrometer	31	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 31	proteomic profiling by mass spectrometer	31	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 31	proteomic profiling by mass spectrometer	31	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 31	proteomic profiling by mass spectrometer	31	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 31	proteomic profiling by mass spectrometer	31	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 31	proteomic profiling by mass spectrometer	31	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 31	proteomic profiling by mass spectrometer	31	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 31	proteomic profiling by mass spectrometer	31	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 31	proteomic profiling by mass spectrometer	31	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 31	proteomic profiling by mass spectrometer	31	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 32	proteomic profiling by mass spectrometer	32	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 32	proteomic profiling by mass spectrometer	32	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 32	proteomic profiling by mass spectrometer	32	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 32	proteomic profiling by mass spectrometer	32	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 32	proteomic profiling by mass spectrometer	32	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 32	proteomic profiling by mass spectrometer	32	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 32	proteomic profiling by mass spectrometer	32	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 32	proteomic profiling by mass spectrometer	32	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 32	proteomic profiling by mass spectrometer	32	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 32	proteomic profiling by mass spectrometer	32	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 33	proteomic profiling by mass spectrometer	33	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 33	proteomic profiling by mass spectrometer	33	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 33	proteomic profiling by mass spectrometer	33	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 33	proteomic profiling by mass spectrometer	33	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 33	proteomic profiling by mass spectrometer	33	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 33	proteomic profiling by mass spectrometer	33	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 33	proteomic profiling by mass spectrometer	33	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 33	proteomic profiling by mass spectrometer	33	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 33	proteomic profiling by mass spectrometer	33	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 33	proteomic profiling by mass spectrometer	33	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 34	proteomic profiling by mass spectrometer	34	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 34	proteomic profiling by mass spectrometer	34	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 34	proteomic profiling by mass spectrometer	34	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 34	proteomic profiling by mass spectrometer	34	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 34	proteomic profiling by mass spectrometer	34	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 34	proteomic profiling by mass spectrometer	34	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 34	proteomic profiling by mass spectrometer	34	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 34	proteomic profiling by mass spectrometer	34	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 34	proteomic profiling by mass spectrometer	34	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 34	proteomic profiling by mass spectrometer	34	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 35	proteomic profiling by mass spectrometer	35	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 35	proteomic profiling by mass spectrometer	35	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 35	proteomic profiling by mass spectrometer	35	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 35	proteomic profiling by mass spectrometer	35	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 35	proteomic profiling by mass spectrometer	35	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 35	proteomic profiling by mass spectrometer	35	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 35	proteomic profiling by mass spectrometer	35	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 35	proteomic profiling by mass spectrometer	35	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 35	proteomic profiling by mass spectrometer	35	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 35	proteomic profiling by mass spectrometer	35	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 36	proteomic profiling by mass spectrometer	36	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 36	proteomic profiling by mass spectrometer	36	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 36	proteomic profiling by mass spectrometer	36	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 36	proteomic profiling by mass spectrometer	36	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 36	proteomic profiling by mass spectrometer	36	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 36	proteomic profiling by mass spectrometer	36	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 36	proteomic profiling by mass spectrometer	36	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 36	proteomic profiling by mass spectrometer	36	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 36	proteomic profiling by mass spectrometer	36	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 36	proteomic profiling by mass spectrometer	36	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 37	proteomic profiling by mass spectrometer	37	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 37	proteomic profiling by mass spectrometer	37	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 37	proteomic profiling by mass spectrometer	37	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 37	proteomic profiling by mass spectrometer	37	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 37	proteomic profiling by mass spectrometer	37	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 37	proteomic profiling by mass spectrometer	37	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 37	proteomic profiling by mass spectrometer	37	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 37	proteomic profiling by mass spectrometer	37	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 37	proteomic profiling by mass spectrometer	37	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 37	proteomic profiling by mass spectrometer	37	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 38	proteomic profiling by mass spectrometer	38	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 38	proteomic profiling by mass spectrometer	38	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 38	proteomic profiling by mass spectrometer	38	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 38	proteomic profiling by mass spectrometer	38	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 38	proteomic profiling by mass spectrometer	38	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 38	proteomic profiling by mass spectrometer	38	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 38	proteomic profiling by mass spectrometer	38	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 38	proteomic profiling by mass spectrometer	38	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 38	proteomic profiling by mass spectrometer	38	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 38	proteomic profiling by mass spectrometer	38	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 39	proteomic profiling by mass spectrometer	39	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 39	proteomic profiling by mass spectrometer	39	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 39	proteomic profiling by mass spectrometer	39	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 39	proteomic profiling by mass spectrometer	39	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 39	proteomic profiling by mass spectrometer	39	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 39	proteomic profiling by mass spectrometer	39	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 39	proteomic profiling by mass spectrometer	39	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 39	proteomic profiling by mass spectrometer	39	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 39	proteomic profiling by mass spectrometer	39	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 39	proteomic profiling by mass spectrometer	39	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 40	proteomic profiling by mass spectrometer	40	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 40	proteomic profiling by mass spectrometer	40	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 40	proteomic profiling by mass spectrometer	40	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 40	proteomic profiling by mass spectrometer	40	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 40	proteomic profiling by mass spectrometer	40	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 40	proteomic profiling by mass spectrometer	40	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 40	proteomic profiling by mass spectrometer	40	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 40	proteomic profiling by mass spectrometer	40	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 40	proteomic profiling by mass spectrometer	40	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 40	proteomic profiling by mass spectrometer	40	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 41	proteomic profiling by mass spectrometer	41	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 41	proteomic profiling by mass spectrometer	41	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 41	proteomic profiling by mass spectrometer	41	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 41	proteomic profiling by mass spectrometer	41	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 41	proteomic profiling by mass spectrometer	41	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 41	proteomic profiling by mass spectrometer	41	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 41	proteomic profiling by mass spectrometer	41	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 41	proteomic profiling by mass spectrometer	41	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 41	proteomic profiling by mass spectrometer	41	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 41	proteomic profiling by mass spectrometer	41	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 42	proteomic profiling by mass spectrometer	42	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 42	proteomic profiling by mass spectrometer	42	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 42	proteomic profiling by mass spectrometer	42	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 42	proteomic profiling by mass spectrometer	42	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 42	proteomic profiling by mass spectrometer	42	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 42	proteomic profiling by mass spectrometer	42	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 42	proteomic profiling by mass spectrometer	42	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 42	proteomic profiling by mass spectrometer	42	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 42	proteomic profiling by mass spectrometer	42	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 42	proteomic profiling by mass spectrometer	42	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 43	proteomic profiling by mass spectrometer	43	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 43	proteomic profiling by mass spectrometer	43	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 43	proteomic profiling by mass spectrometer	43	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 43	proteomic profiling by mass spectrometer	43	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 43	proteomic profiling by mass spectrometer	43	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 43	proteomic profiling by mass spectrometer	43	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 43	proteomic profiling by mass spectrometer	43	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 43	proteomic profiling by mass spectrometer	43	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 43	proteomic profiling by mass spectrometer	43	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 43	proteomic profiling by mass spectrometer	43	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 44	proteomic profiling by mass spectrometer	44	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 44	proteomic profiling by mass spectrometer	44	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 44	proteomic profiling by mass spectrometer	44	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 44	proteomic profiling by mass spectrometer	44	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 44	proteomic profiling by mass spectrometer	44	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 44	proteomic profiling by mass spectrometer	44	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 44	proteomic profiling by mass spectrometer	44	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 44	proteomic profiling by mass spectrometer	44	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 44	proteomic profiling by mass spectrometer	44	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 44	proteomic profiling by mass spectrometer	44	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 45	proteomic profiling by mass spectrometer	45	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 45	proteomic profiling by mass spectrometer	45	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 45	proteomic profiling by mass spectrometer	45	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 45	proteomic profiling by mass spectrometer	45	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 45	proteomic profiling by mass spectrometer	45	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 45	proteomic profiling by mass spectrometer	45	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 45	proteomic profiling by mass spectrometer	45	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 45	proteomic profiling by mass spectrometer	45	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 45	proteomic profiling by mass spectrometer	45	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 45	proteomic profiling by mass spectrometer	45	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 46	proteomic profiling by mass spectrometer	46	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 46	proteomic profiling by mass spectrometer	46	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 46	proteomic profiling by mass spectrometer	46	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 46	proteomic profiling by mass spectrometer	46	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 46	proteomic profiling by mass spectrometer	46	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 46	proteomic profiling by mass spectrometer	46	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 46	proteomic profiling by mass spectrometer	46	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 46	proteomic profiling by mass spectrometer	46	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 46	proteomic profiling by mass spectrometer	46	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 46	proteomic profiling by mass spectrometer	46	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 47	proteomic profiling by mass spectrometer	47	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 47	proteomic profiling by mass spectrometer	47	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 47	proteomic profiling by mass spectrometer	47	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 47	proteomic profiling by mass spectrometer	47	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 47	proteomic profiling by mass spectrometer	47	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 47	proteomic profiling by mass spectrometer	47	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 47	proteomic profiling by mass spectrometer	47	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 47	proteomic profiling by mass spectrometer	47	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 47	proteomic profiling by mass spectrometer	47	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 47	proteomic profiling by mass spectrometer	47	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 48	proteomic profiling by mass spectrometer	48	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 48	proteomic profiling by mass spectrometer	48	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 48	proteomic profiling by mass spectrometer	48	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 48	proteomic profiling by mass spectrometer	48	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 48	proteomic profiling by mass spectrometer	48	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 48	proteomic profiling by mass spectrometer	48	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 48	proteomic profiling by mass spectrometer	48	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 48	proteomic profiling by mass spectrometer	48	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 48	proteomic profiling by mass spectrometer	48	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 48	proteomic profiling by mass spectrometer	48	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 49	proteomic profiling by mass spectrometer	49	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 49	proteomic profiling by mass spectrometer	49	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 49	proteomic profiling by mass spectrometer	49	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 49	proteomic profiling by mass spectrometer	49	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 49	proteomic profiling by mass spectrometer	49	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 49	proteomic profiling by mass spectrometer	49	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 49	proteomic profiling by mass spectrometer	49	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 49	proteomic profiling by mass spectrometer	49	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 49	proteomic profiling by mass spectrometer	49	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 49	proteomic profiling by mass spectrometer	49	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 50	proteomic profiling by mass spectrometer	50	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 50	proteomic profiling by mass spectrometer	50	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 50	proteomic profiling by mass spectrometer	50	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 50	proteomic profiling by mass spectrometer	50	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 50	proteomic profiling by mass spectrometer	50	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 50	proteomic profiling by mass spectrometer	50	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 50	proteomic profiling by mass spectrometer	50	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 50	proteomic profiling by mass spectrometer	50	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 50	proteomic profiling by mass spectrometer	50	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 50	proteomic profiling by mass spectrometer	50	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 51	proteomic profiling by mass spectrometer	51	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 51	proteomic profiling by mass spectrometer	51	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 51	proteomic profiling by mass spectrometer	51	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 51	proteomic profiling by mass spectrometer	51	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 51	proteomic profiling by mass spectrometer	51	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 51	proteomic profiling by mass spectrometer	51	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 51	proteomic profiling by mass spectrometer	51	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 51	proteomic profiling by mass spectrometer	51	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 51	proteomic profiling by mass spectrometer	51	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 51	proteomic profiling by mass spectrometer	51	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 52	proteomic profiling by mass spectrometer	52	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 52	proteomic profiling by mass spectrometer	52	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 52	proteomic profiling by mass spectrometer	52	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 52	proteomic profiling by mass spectrometer	52	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 52	proteomic profiling by mass spectrometer	52	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 52	proteomic profiling by mass spectrometer	52	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 52	proteomic profiling by mass spectrometer	52	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 52	proteomic profiling by mass spectrometer	52	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 52	proteomic profiling by mass spectrometer	52	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 52	proteomic profiling by mass spectrometer	52	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 53	proteomic profiling by mass spectrometer	53	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 53	proteomic profiling by mass spectrometer	53	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 53	proteomic profiling by mass spectrometer	53	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 53	proteomic profiling by mass spectrometer	53	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 53	proteomic profiling by mass spectrometer	53	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 53	proteomic profiling by mass spectrometer	53	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 53	proteomic profiling by mass spectrometer	53	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 53	proteomic profiling by mass spectrometer	53	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 53	proteomic profiling by mass spectrometer	53	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 53	proteomic profiling by mass spectrometer	53	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 54	proteomic profiling by mass spectrometer	54	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 54	proteomic profiling by mass spectrometer	54	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 54	proteomic profiling by mass spectrometer	54	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 54	proteomic profiling by mass spectrometer	54	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 54	proteomic profiling by mass spectrometer	54	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 54	proteomic profiling by mass spectrometer	54	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 54	proteomic profiling by mass spectrometer	54	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 54	proteomic profiling by mass spectrometer	54	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 54	proteomic profiling by mass spectrometer	54	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 54	proteomic profiling by mass spectrometer	54	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 55	proteomic profiling by mass spectrometer	55	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 55	proteomic profiling by mass spectrometer	55	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 55	proteomic profiling by mass spectrometer	55	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 55	proteomic profiling by mass spectrometer	55	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 55	proteomic profiling by mass spectrometer	55	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 55	proteomic profiling by mass spectrometer	55	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 55	proteomic profiling by mass spectrometer	55	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 55	proteomic profiling by mass spectrometer	55	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 55	proteomic profiling by mass spectrometer	55	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 55	proteomic profiling by mass spectrometer	55	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 56	proteomic profiling by mass spectrometer	56	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 56	proteomic profiling by mass spectrometer	56	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 56	proteomic profiling by mass spectrometer	56	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 56	proteomic profiling by mass spectrometer	56	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 56	proteomic profiling by mass spectrometer	56	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 56	proteomic profiling by mass spectrometer	56	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 56	proteomic profiling by mass spectrometer	56	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 56	proteomic profiling by mass spectrometer	56	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 56	proteomic profiling by mass spectrometer	56	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 56	proteomic profiling by mass spectrometer	56	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 57	proteomic profiling by mass spectrometer	57	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 57	proteomic profiling by mass spectrometer	57	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 57	proteomic profiling by mass spectrometer	57	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 57	proteomic profiling by mass spectrometer	57	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 57	proteomic profiling by mass spectrometer	57	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 57	proteomic profiling by mass spectrometer	57	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 57	proteomic profiling by mass spectrometer	57	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 57	proteomic profiling by mass spectrometer	57	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 57	proteomic profiling by mass spectrometer	57	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 57	proteomic profiling by mass spectrometer	57	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 58	proteomic profiling by mass spectrometer	58	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 58	proteomic profiling by mass spectrometer	58	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 58	proteomic profiling by mass spectrometer	58	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 58	proteomic profiling by mass spectrometer	58	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 58	proteomic profiling by mass spectrometer	58	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 58	proteomic profiling by mass spectrometer	58	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 58	proteomic profiling by mass spectrometer	58	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 58	proteomic profiling by mass spectrometer	58	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 58	proteomic profiling by mass spectrometer	58	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 58	proteomic profiling by mass spectrometer	58	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 59	proteomic profiling by mass spectrometer	59	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 59	proteomic profiling by mass spectrometer	59	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 59	proteomic profiling by mass spectrometer	59	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 59	proteomic profiling by mass spectrometer	59	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 59	proteomic profiling by mass spectrometer	59	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 59	proteomic profiling by mass spectrometer	59	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 59	proteomic profiling by mass spectrometer	59	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 59	proteomic profiling by mass spectrometer	59	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 59	proteomic profiling by mass spectrometer	59	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 59	proteomic profiling by mass spectrometer	59	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 60	proteomic profiling by mass spectrometer	60	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 60	proteomic profiling by mass spectrometer	60	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 60	proteomic profiling by mass spectrometer	60	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 60	proteomic profiling by mass spectrometer	60	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 60	proteomic profiling by mass spectrometer	60	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 60	proteomic profiling by mass spectrometer	60	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 60	proteomic profiling by mass spectrometer	60	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 60	proteomic profiling by mass spectrometer	60	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 60	proteomic profiling by mass spectrometer	60	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 60	proteomic profiling by mass spectrometer	60	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 61	proteomic profiling by mass spectrometer	61	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 61	proteomic profiling by mass spectrometer	61	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 61	proteomic profiling by mass spectrometer	61	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 61	proteomic profiling by mass spectrometer	61	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 61	proteomic profiling by mass spectrometer	61	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 61	proteomic profiling by mass spectrometer	61	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 61	proteomic profiling by mass spectrometer	61	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 61	proteomic profiling by mass spectrometer	61	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 61	proteomic profiling by mass spectrometer	61	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 61	proteomic profiling by mass spectrometer	61	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 62	proteomic profiling by mass spectrometer	62	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 62	proteomic profiling by mass spectrometer	62	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 62	proteomic profiling by mass spectrometer	62	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 62	proteomic profiling by mass spectrometer	62	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 62	proteomic profiling by mass spectrometer	62	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 62	proteomic profiling by mass spectrometer	62	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 62	proteomic profiling by mass spectrometer	62	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 62	proteomic profiling by mass spectrometer	62	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 62	proteomic profiling by mass spectrometer	62	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 62	proteomic profiling by mass spectrometer	62	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 63	proteomic profiling by mass spectrometer	63	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 63	proteomic profiling by mass spectrometer	63	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 63	proteomic profiling by mass spectrometer	63	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 63	proteomic profiling by mass spectrometer	63	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 63	proteomic profiling by mass spectrometer	63	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 63	proteomic profiling by mass spectrometer	63	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 63	proteomic profiling by mass spectrometer	63	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 63	proteomic profiling by mass spectrometer	63	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 63	proteomic profiling by mass spectrometer	63	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 63	proteomic profiling by mass spectrometer	63	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 64	proteomic profiling by mass spectrometer	64	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 64	proteomic profiling by mass spectrometer	64	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 64	proteomic profiling by mass spectrometer	64	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 64	proteomic profiling by mass spectrometer	64	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 64	proteomic profiling by mass spectrometer	64	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 64	proteomic profiling by mass spectrometer	64	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 64	proteomic profiling by mass spectrometer	64	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 64	proteomic profiling by mass spectrometer	64	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 64	proteomic profiling by mass spectrometer	64	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 64	proteomic profiling by mass spectrometer	64	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 65	proteomic profiling by mass spectrometer	65	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 65	proteomic profiling by mass spectrometer	65	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 65	proteomic profiling by mass spectrometer	65	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 65	proteomic profiling by mass spectrometer	65	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 65	proteomic profiling by mass spectrometer	65	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 65	proteomic profiling by mass spectrometer	65	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 65	proteomic profiling by mass spectrometer	65	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 65	proteomic profiling by mass spectrometer	65	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 65	proteomic profiling by mass spectrometer	65	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 65	proteomic profiling by mass spectrometer	65	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 66	proteomic profiling by mass spectrometer	66	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 66	proteomic profiling by mass spectrometer	66	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 66	proteomic profiling by mass spectrometer	66	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 66	proteomic profiling by mass spectrometer	66	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 66	proteomic profiling by mass spectrometer	66	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 66	proteomic profiling by mass spectrometer	66	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 66	proteomic profiling by mass spectrometer	66	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 66	proteomic profiling by mass spectrometer	66	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 66	proteomic profiling by mass spectrometer	66	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 66	proteomic profiling by mass spectrometer	66	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 67	proteomic profiling by mass spectrometer	67	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 67	proteomic profiling by mass spectrometer	67	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 67	proteomic profiling by mass spectrometer	67	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 67	proteomic profiling by mass spectrometer	67	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 67	proteomic profiling by mass spectrometer	67	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 67	proteomic profiling by mass spectrometer	67	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 67	proteomic profiling by mass spectrometer	67	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 67	proteomic profiling by mass spectrometer	67	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 67	proteomic profiling by mass spectrometer	67	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 67	proteomic profiling by mass spectrometer	67	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 68	proteomic profiling by mass spectrometer	68	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 68	proteomic profiling by mass spectrometer	68	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 68	proteomic profiling by mass spectrometer	68	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 68	proteomic profiling by mass spectrometer	68	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 68	proteomic profiling by mass spectrometer	68	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 68	proteomic profiling by mass spectrometer	68	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 68	proteomic profiling by mass spectrometer	68	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 68	proteomic profiling by mass spectrometer	68	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 68	proteomic profiling by mass spectrometer	68	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 68	proteomic profiling by mass spectrometer	68	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 69	proteomic profiling by mass spectrometer	69	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 69	proteomic profiling by mass spectrometer	69	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 69	proteomic profiling by mass spectrometer	69	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 69	proteomic profiling by mass spectrometer	69	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 69	proteomic profiling by mass spectrometer	69	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 69	proteomic profiling by mass spectrometer	69	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 69	proteomic profiling by mass spectrometer	69	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 69	proteomic profiling by mass spectrometer	69	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 69	proteomic profiling by mass spectrometer	69	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 69	proteomic profiling by mass spectrometer	69	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 70	proteomic profiling by mass spectrometer	70	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 70	proteomic profiling by mass spectrometer	70	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 70	proteomic profiling by mass spectrometer	70	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 70	proteomic profiling by mass spectrometer	70	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 70	proteomic profiling by mass spectrometer	70	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 70	proteomic profiling by mass spectrometer	70	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 70	proteomic profiling by mass spectrometer	70	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 70	proteomic profiling by mass spectrometer	70	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 70	proteomic profiling by mass spectrometer	70	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 70	proteomic profiling by mass spectrometer	70	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 71	proteomic profiling by mass spectrometer	71	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 71	proteomic profiling by mass spectrometer	71	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 71	proteomic profiling by mass spectrometer	71	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 71	proteomic profiling by mass spectrometer	71	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 71	proteomic profiling by mass spectrometer	71	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 71	proteomic profiling by mass spectrometer	71	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 71	proteomic profiling by mass spectrometer	71	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 71	proteomic profiling by mass spectrometer	71	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 71	proteomic profiling by mass spectrometer	71	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 71	proteomic profiling by mass spectrometer	71	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	run 72	proteomic profiling by mass spectrometer	72	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	run 72	proteomic profiling by mass spectrometer	72	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	run 72	proteomic profiling by mass spectrometer	72	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	run 72	proteomic profiling by mass spectrometer	72	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	run 72	proteomic profiling by mass spectrometer	72	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	run 72	proteomic profiling by mass spectrometer	72	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	run 72	proteomic profiling by mass spectrometer	72	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	run 72	proteomic profiling by mass spectrometer	72	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	run 72	proteomic profiling by mass spectrometer	72	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	run 72	proteomic profiling by mass spectrometer	72	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 73	proteomic profiling by mass spectrometer	1	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 73	proteomic profiling by mass spectrometer	1	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 73	proteomic profiling by mass spectrometer	1	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 73	proteomic profiling by mass spectrometer	1	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 73	proteomic profiling by mass spectrometer	1	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 73	proteomic profiling by mass spectrometer	1	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 73	proteomic profiling by mass spectrometer	1	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 73	proteomic profiling by mass spectrometer	1	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 73	proteomic profiling by mass spectrometer	1	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 73	proteomic profiling by mass spectrometer	1	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 74	proteomic profiling by mass spectrometer	2	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 74	proteomic profiling by mass spectrometer	2	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 74	proteomic profiling by mass spectrometer	2	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 74	proteomic profiling by mass spectrometer	2	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 74	proteomic profiling by mass spectrometer	2	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 74	proteomic profiling by mass spectrometer	2	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 74	proteomic profiling by mass spectrometer	2	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 74	proteomic profiling by mass spectrometer	2	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 74	proteomic profiling by mass spectrometer	2	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 74	proteomic profiling by mass spectrometer	2	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 75	proteomic profiling by mass spectrometer	3	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 75	proteomic profiling by mass spectrometer	3	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 75	proteomic profiling by mass spectrometer	3	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 75	proteomic profiling by mass spectrometer	3	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 75	proteomic profiling by mass spectrometer	3	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 75	proteomic profiling by mass spectrometer	3	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 75	proteomic profiling by mass spectrometer	3	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 75	proteomic profiling by mass spectrometer	3	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 75	proteomic profiling by mass spectrometer	3	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 75	proteomic profiling by mass spectrometer	3	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 76	proteomic profiling by mass spectrometer	4	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 76	proteomic profiling by mass spectrometer	4	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 76	proteomic profiling by mass spectrometer	4	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 76	proteomic profiling by mass spectrometer	4	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 76	proteomic profiling by mass spectrometer	4	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 76	proteomic profiling by mass spectrometer	4	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 76	proteomic profiling by mass spectrometer	4	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 76	proteomic profiling by mass spectrometer	4	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 76	proteomic profiling by mass spectrometer	4	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 76	proteomic profiling by mass spectrometer	4	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 77	proteomic profiling by mass spectrometer	5	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 77	proteomic profiling by mass spectrometer	5	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 77	proteomic profiling by mass spectrometer	5	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 77	proteomic profiling by mass spectrometer	5	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 77	proteomic profiling by mass spectrometer	5	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 77	proteomic profiling by mass spectrometer	5	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 77	proteomic profiling by mass spectrometer	5	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 77	proteomic profiling by mass spectrometer	5	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 77	proteomic profiling by mass spectrometer	5	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 77	proteomic profiling by mass spectrometer	5	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 78	proteomic profiling by mass spectrometer	6	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 78	proteomic profiling by mass spectrometer	6	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 78	proteomic profiling by mass spectrometer	6	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 78	proteomic profiling by mass spectrometer	6	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 78	proteomic profiling by mass spectrometer	6	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 78	proteomic profiling by mass spectrometer	6	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 78	proteomic profiling by mass spectrometer	6	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 78	proteomic profiling by mass spectrometer	6	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 78	proteomic profiling by mass spectrometer	6	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 78	proteomic profiling by mass spectrometer	6	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 79	proteomic profiling by mass spectrometer	7	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 79	proteomic profiling by mass spectrometer	7	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 79	proteomic profiling by mass spectrometer	7	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 79	proteomic profiling by mass spectrometer	7	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 79	proteomic profiling by mass spectrometer	7	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 79	proteomic profiling by mass spectrometer	7	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 79	proteomic profiling by mass spectrometer	7	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 79	proteomic profiling by mass spectrometer	7	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 79	proteomic profiling by mass spectrometer	7	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 79	proteomic profiling by mass spectrometer	7	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 80	proteomic profiling by mass spectrometer	8	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 80	proteomic profiling by mass spectrometer	8	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 80	proteomic profiling by mass spectrometer	8	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 80	proteomic profiling by mass spectrometer	8	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 80	proteomic profiling by mass spectrometer	8	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 80	proteomic profiling by mass spectrometer	8	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 80	proteomic profiling by mass spectrometer	8	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 80	proteomic profiling by mass spectrometer	8	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 80	proteomic profiling by mass spectrometer	8	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 80	proteomic profiling by mass spectrometer	8	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 81	proteomic profiling by mass spectrometer	9	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 81	proteomic profiling by mass spectrometer	9	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 81	proteomic profiling by mass spectrometer	9	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 81	proteomic profiling by mass spectrometer	9	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 81	proteomic profiling by mass spectrometer	9	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 81	proteomic profiling by mass spectrometer	9	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 81	proteomic profiling by mass spectrometer	9	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 81	proteomic profiling by mass spectrometer	9	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 81	proteomic profiling by mass spectrometer	9	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 81	proteomic profiling by mass spectrometer	9	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 82	proteomic profiling by mass spectrometer	10	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 82	proteomic profiling by mass spectrometer	10	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 82	proteomic profiling by mass spectrometer	10	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 82	proteomic profiling by mass spectrometer	10	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 82	proteomic profiling by mass spectrometer	10	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 82	proteomic profiling by mass spectrometer	10	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 82	proteomic profiling by mass spectrometer	10	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 82	proteomic profiling by mass spectrometer	10	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 82	proteomic profiling by mass spectrometer	10	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 82	proteomic profiling by mass spectrometer	10	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 83	proteomic profiling by mass spectrometer	11	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 83	proteomic profiling by mass spectrometer	11	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 83	proteomic profiling by mass spectrometer	11	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 83	proteomic profiling by mass spectrometer	11	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 83	proteomic profiling by mass spectrometer	11	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 83	proteomic profiling by mass spectrometer	11	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 83	proteomic profiling by mass spectrometer	11	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 83	proteomic profiling by mass spectrometer	11	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 83	proteomic profiling by mass spectrometer	11	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 83	proteomic profiling by mass spectrometer	11	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 84	proteomic profiling by mass spectrometer	12	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 84	proteomic profiling by mass spectrometer	12	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 84	proteomic profiling by mass spectrometer	12	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 84	proteomic profiling by mass spectrometer	12	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 84	proteomic profiling by mass spectrometer	12	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 84	proteomic profiling by mass spectrometer	12	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 84	proteomic profiling by mass spectrometer	12	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 84	proteomic profiling by mass spectrometer	12	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 84	proteomic profiling by mass spectrometer	12	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 84	proteomic profiling by mass spectrometer	12	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 85	proteomic profiling by mass spectrometer	13	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 85	proteomic profiling by mass spectrometer	13	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 85	proteomic profiling by mass spectrometer	13	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 85	proteomic profiling by mass spectrometer	13	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 85	proteomic profiling by mass spectrometer	13	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 85	proteomic profiling by mass spectrometer	13	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 85	proteomic profiling by mass spectrometer	13	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 85	proteomic profiling by mass spectrometer	13	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 85	proteomic profiling by mass spectrometer	13	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 85	proteomic profiling by mass spectrometer	13	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 86	proteomic profiling by mass spectrometer	14	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 86	proteomic profiling by mass spectrometer	14	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 86	proteomic profiling by mass spectrometer	14	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 86	proteomic profiling by mass spectrometer	14	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 86	proteomic profiling by mass spectrometer	14	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 86	proteomic profiling by mass spectrometer	14	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 86	proteomic profiling by mass spectrometer	14	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 86	proteomic profiling by mass spectrometer	14	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 86	proteomic profiling by mass spectrometer	14	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 86	proteomic profiling by mass spectrometer	14	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 87	proteomic profiling by mass spectrometer	15	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 87	proteomic profiling by mass spectrometer	15	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 87	proteomic profiling by mass spectrometer	15	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 87	proteomic profiling by mass spectrometer	15	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 87	proteomic profiling by mass spectrometer	15	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 87	proteomic profiling by mass spectrometer	15	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 87	proteomic profiling by mass spectrometer	15	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 87	proteomic profiling by mass spectrometer	15	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 87	proteomic profiling by mass spectrometer	15	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 87	proteomic profiling by mass spectrometer	15	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 88	proteomic profiling by mass spectrometer	16	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 88	proteomic profiling by mass spectrometer	16	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 88	proteomic profiling by mass spectrometer	16	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 88	proteomic profiling by mass spectrometer	16	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 88	proteomic profiling by mass spectrometer	16	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 88	proteomic profiling by mass spectrometer	16	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 88	proteomic profiling by mass spectrometer	16	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 88	proteomic profiling by mass spectrometer	16	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 88	proteomic profiling by mass spectrometer	16	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 88	proteomic profiling by mass spectrometer	16	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 89	proteomic profiling by mass spectrometer	17	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 89	proteomic profiling by mass spectrometer	17	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 89	proteomic profiling by mass spectrometer	17	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 89	proteomic profiling by mass spectrometer	17	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 89	proteomic profiling by mass spectrometer	17	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 89	proteomic profiling by mass spectrometer	17	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 89	proteomic profiling by mass spectrometer	17	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 89	proteomic profiling by mass spectrometer	17	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 89	proteomic profiling by mass spectrometer	17	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 89	proteomic profiling by mass spectrometer	17	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 90	proteomic profiling by mass spectrometer	18	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 90	proteomic profiling by mass spectrometer	18	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 90	proteomic profiling by mass spectrometer	18	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 90	proteomic profiling by mass spectrometer	18	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 90	proteomic profiling by mass spectrometer	18	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 90	proteomic profiling by mass spectrometer	18	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 90	proteomic profiling by mass spectrometer	18	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 90	proteomic profiling by mass spectrometer	18	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 90	proteomic profiling by mass spectrometer	18	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 90	proteomic profiling by mass spectrometer	18	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 91	proteomic profiling by mass spectrometer	19	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 91	proteomic profiling by mass spectrometer	19	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 91	proteomic profiling by mass spectrometer	19	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 91	proteomic profiling by mass spectrometer	19	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 91	proteomic profiling by mass spectrometer	19	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 91	proteomic profiling by mass spectrometer	19	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 91	proteomic profiling by mass spectrometer	19	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 91	proteomic profiling by mass spectrometer	19	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 91	proteomic profiling by mass spectrometer	19	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 91	proteomic profiling by mass spectrometer	19	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 92	proteomic profiling by mass spectrometer	20	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 92	proteomic profiling by mass spectrometer	20	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 92	proteomic profiling by mass spectrometer	20	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 92	proteomic profiling by mass spectrometer	20	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 92	proteomic profiling by mass spectrometer	20	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 92	proteomic profiling by mass spectrometer	20	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 92	proteomic profiling by mass spectrometer	20	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 92	proteomic profiling by mass spectrometer	20	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 92	proteomic profiling by mass spectrometer	20	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 92	proteomic profiling by mass spectrometer	20	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 93	proteomic profiling by mass spectrometer	21	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 93	proteomic profiling by mass spectrometer	21	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 93	proteomic profiling by mass spectrometer	21	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 93	proteomic profiling by mass spectrometer	21	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 93	proteomic profiling by mass spectrometer	21	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 93	proteomic profiling by mass spectrometer	21	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 93	proteomic profiling by mass spectrometer	21	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 93	proteomic profiling by mass spectrometer	21	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 93	proteomic profiling by mass spectrometer	21	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 93	proteomic profiling by mass spectrometer	21	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 94	proteomic profiling by mass spectrometer	22	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 94	proteomic profiling by mass spectrometer	22	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 94	proteomic profiling by mass spectrometer	22	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 94	proteomic profiling by mass spectrometer	22	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 94	proteomic profiling by mass spectrometer	22	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 94	proteomic profiling by mass spectrometer	22	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 94	proteomic profiling by mass spectrometer	22	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 94	proteomic profiling by mass spectrometer	22	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 94	proteomic profiling by mass spectrometer	22	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 94	proteomic profiling by mass spectrometer	22	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 95	proteomic profiling by mass spectrometer	23	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 95	proteomic profiling by mass spectrometer	23	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 95	proteomic profiling by mass spectrometer	23	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 95	proteomic profiling by mass spectrometer	23	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 95	proteomic profiling by mass spectrometer	23	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 95	proteomic profiling by mass spectrometer	23	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 95	proteomic profiling by mass spectrometer	23	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 95	proteomic profiling by mass spectrometer	23	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 95	proteomic profiling by mass spectrometer	23	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 95	proteomic profiling by mass spectrometer	23	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 96	proteomic profiling by mass spectrometer	24	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 96	proteomic profiling by mass spectrometer	24	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 96	proteomic profiling by mass spectrometer	24	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 96	proteomic profiling by mass spectrometer	24	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 96	proteomic profiling by mass spectrometer	24	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 96	proteomic profiling by mass spectrometer	24	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 96	proteomic profiling by mass spectrometer	24	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 96	proteomic profiling by mass spectrometer	24	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 96	proteomic profiling by mass spectrometer	24	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 96	proteomic profiling by mass spectrometer	24	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 97	proteomic profiling by mass spectrometer	25	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 97	proteomic profiling by mass spectrometer	25	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 97	proteomic profiling by mass spectrometer	25	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 97	proteomic profiling by mass spectrometer	25	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 97	proteomic profiling by mass spectrometer	25	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 97	proteomic profiling by mass spectrometer	25	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 97	proteomic profiling by mass spectrometer	25	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 97	proteomic profiling by mass spectrometer	25	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 97	proteomic profiling by mass spectrometer	25	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 97	proteomic profiling by mass spectrometer	25	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 98	proteomic profiling by mass spectrometer	26	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 98	proteomic profiling by mass spectrometer	26	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 98	proteomic profiling by mass spectrometer	26	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 98	proteomic profiling by mass spectrometer	26	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 98	proteomic profiling by mass spectrometer	26	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 98	proteomic profiling by mass spectrometer	26	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 98	proteomic profiling by mass spectrometer	26	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 98	proteomic profiling by mass spectrometer	26	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 98	proteomic profiling by mass spectrometer	26	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 98	proteomic profiling by mass spectrometer	26	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 99	proteomic profiling by mass spectrometer	27	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 99	proteomic profiling by mass spectrometer	27	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 99	proteomic profiling by mass spectrometer	27	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 99	proteomic profiling by mass spectrometer	27	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 99	proteomic profiling by mass spectrometer	27	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 99	proteomic profiling by mass spectrometer	27	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 99	proteomic profiling by mass spectrometer	27	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 99	proteomic profiling by mass spectrometer	27	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 99	proteomic profiling by mass spectrometer	27	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 99	proteomic profiling by mass spectrometer	27	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 100	proteomic profiling by mass spectrometer	28	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 100	proteomic profiling by mass spectrometer	28	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 100	proteomic profiling by mass spectrometer	28	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 100	proteomic profiling by mass spectrometer	28	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 100	proteomic profiling by mass spectrometer	28	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 100	proteomic profiling by mass spectrometer	28	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 100	proteomic profiling by mass spectrometer	28	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 100	proteomic profiling by mass spectrometer	28	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 100	proteomic profiling by mass spectrometer	28	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 100	proteomic profiling by mass spectrometer	28	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 101	proteomic profiling by mass spectrometer	29	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 101	proteomic profiling by mass spectrometer	29	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 101	proteomic profiling by mass spectrometer	29	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 101	proteomic profiling by mass spectrometer	29	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 101	proteomic profiling by mass spectrometer	29	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 101	proteomic profiling by mass spectrometer	29	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 101	proteomic profiling by mass spectrometer	29	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 101	proteomic profiling by mass spectrometer	29	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 101	proteomic profiling by mass spectrometer	29	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 101	proteomic profiling by mass spectrometer	29	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 102	proteomic profiling by mass spectrometer	30	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 102	proteomic profiling by mass spectrometer	30	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 102	proteomic profiling by mass spectrometer	30	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 102	proteomic profiling by mass spectrometer	30	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 102	proteomic profiling by mass spectrometer	30	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 102	proteomic profiling by mass spectrometer	30	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 102	proteomic profiling by mass spectrometer	30	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 102	proteomic profiling by mass spectrometer	30	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 102	proteomic profiling by mass spectrometer	30	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 102	proteomic profiling by mass spectrometer	30	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 103	proteomic profiling by mass spectrometer	31	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 103	proteomic profiling by mass spectrometer	31	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 103	proteomic profiling by mass spectrometer	31	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 103	proteomic profiling by mass spectrometer	31	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 103	proteomic profiling by mass spectrometer	31	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 103	proteomic profiling by mass spectrometer	31	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 103	proteomic profiling by mass spectrometer	31	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 103	proteomic profiling by mass spectrometer	31	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 103	proteomic profiling by mass spectrometer	31	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 103	proteomic profiling by mass spectrometer	31	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 104	proteomic profiling by mass spectrometer	32	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 104	proteomic profiling by mass spectrometer	32	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 104	proteomic profiling by mass spectrometer	32	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 104	proteomic profiling by mass spectrometer	32	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 104	proteomic profiling by mass spectrometer	32	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 104	proteomic profiling by mass spectrometer	32	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 104	proteomic profiling by mass spectrometer	32	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 104	proteomic profiling by mass spectrometer	32	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 104	proteomic profiling by mass spectrometer	32	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 104	proteomic profiling by mass spectrometer	32	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 105	proteomic profiling by mass spectrometer	33	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 105	proteomic profiling by mass spectrometer	33	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 105	proteomic profiling by mass spectrometer	33	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 105	proteomic profiling by mass spectrometer	33	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 105	proteomic profiling by mass spectrometer	33	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 105	proteomic profiling by mass spectrometer	33	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 105	proteomic profiling by mass spectrometer	33	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 105	proteomic profiling by mass spectrometer	33	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 105	proteomic profiling by mass spectrometer	33	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 105	proteomic profiling by mass spectrometer	33	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 106	proteomic profiling by mass spectrometer	34	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 106	proteomic profiling by mass spectrometer	34	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 106	proteomic profiling by mass spectrometer	34	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 106	proteomic profiling by mass spectrometer	34	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 106	proteomic profiling by mass spectrometer	34	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 106	proteomic profiling by mass spectrometer	34	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 106	proteomic profiling by mass spectrometer	34	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 106	proteomic profiling by mass spectrometer	34	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 106	proteomic profiling by mass spectrometer	34	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 106	proteomic profiling by mass spectrometer	34	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 107	proteomic profiling by mass spectrometer	35	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 107	proteomic profiling by mass spectrometer	35	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 107	proteomic profiling by mass spectrometer	35	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 107	proteomic profiling by mass spectrometer	35	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 107	proteomic profiling by mass spectrometer	35	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 107	proteomic profiling by mass spectrometer	35	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 107	proteomic profiling by mass spectrometer	35	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 107	proteomic profiling by mass spectrometer	35	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 107	proteomic profiling by mass spectrometer	35	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 107	proteomic profiling by mass spectrometer	35	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 108	proteomic profiling by mass spectrometer	36	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 108	proteomic profiling by mass spectrometer	36	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 108	proteomic profiling by mass spectrometer	36	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 108	proteomic profiling by mass spectrometer	36	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 108	proteomic profiling by mass spectrometer	36	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 108	proteomic profiling by mass spectrometer	36	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 108	proteomic profiling by mass spectrometer	36	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 108	proteomic profiling by mass spectrometer	36	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 108	proteomic profiling by mass spectrometer	36	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 108	proteomic profiling by mass spectrometer	36	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 109	proteomic profiling by mass spectrometer	37	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 109	proteomic profiling by mass spectrometer	37	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 109	proteomic profiling by mass spectrometer	37	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 109	proteomic profiling by mass spectrometer	37	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 109	proteomic profiling by mass spectrometer	37	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 109	proteomic profiling by mass spectrometer	37	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 109	proteomic profiling by mass spectrometer	37	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 109	proteomic profiling by mass spectrometer	37	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 109	proteomic profiling by mass spectrometer	37	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 109	proteomic profiling by mass spectrometer	37	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 110	proteomic profiling by mass spectrometer	38	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 110	proteomic profiling by mass spectrometer	38	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 110	proteomic profiling by mass spectrometer	38	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 110	proteomic profiling by mass spectrometer	38	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 110	proteomic profiling by mass spectrometer	38	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 110	proteomic profiling by mass spectrometer	38	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 110	proteomic profiling by mass spectrometer	38	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 110	proteomic profiling by mass spectrometer	38	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 110	proteomic profiling by mass spectrometer	38	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 110	proteomic profiling by mass spectrometer	38	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 111	proteomic profiling by mass spectrometer	39	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 111	proteomic profiling by mass spectrometer	39	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 111	proteomic profiling by mass spectrometer	39	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 111	proteomic profiling by mass spectrometer	39	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 111	proteomic profiling by mass spectrometer	39	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 111	proteomic profiling by mass spectrometer	39	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 111	proteomic profiling by mass spectrometer	39	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 111	proteomic profiling by mass spectrometer	39	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 111	proteomic profiling by mass spectrometer	39	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 111	proteomic profiling by mass spectrometer	39	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 112	proteomic profiling by mass spectrometer	40	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 112	proteomic profiling by mass spectrometer	40	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 112	proteomic profiling by mass spectrometer	40	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 112	proteomic profiling by mass spectrometer	40	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 112	proteomic profiling by mass spectrometer	40	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 112	proteomic profiling by mass spectrometer	40	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 112	proteomic profiling by mass spectrometer	40	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 112	proteomic profiling by mass spectrometer	40	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 112	proteomic profiling by mass spectrometer	40	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 112	proteomic profiling by mass spectrometer	40	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 113	proteomic profiling by mass spectrometer	41	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 113	proteomic profiling by mass spectrometer	41	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 113	proteomic profiling by mass spectrometer	41	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 113	proteomic profiling by mass spectrometer	41	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 113	proteomic profiling by mass spectrometer	41	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 113	proteomic profiling by mass spectrometer	41	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 113	proteomic profiling by mass spectrometer	41	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 113	proteomic profiling by mass spectrometer	41	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 113	proteomic profiling by mass spectrometer	41	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 113	proteomic profiling by mass spectrometer	41	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 114	proteomic profiling by mass spectrometer	42	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 114	proteomic profiling by mass spectrometer	42	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 114	proteomic profiling by mass spectrometer	42	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 114	proteomic profiling by mass spectrometer	42	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 114	proteomic profiling by mass spectrometer	42	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 114	proteomic profiling by mass spectrometer	42	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 114	proteomic profiling by mass spectrometer	42	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 114	proteomic profiling by mass spectrometer	42	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 114	proteomic profiling by mass spectrometer	42	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 114	proteomic profiling by mass spectrometer	42	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 115	proteomic profiling by mass spectrometer	43	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 115	proteomic profiling by mass spectrometer	43	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 115	proteomic profiling by mass spectrometer	43	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 115	proteomic profiling by mass spectrometer	43	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 115	proteomic profiling by mass spectrometer	43	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 115	proteomic profiling by mass spectrometer	43	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 115	proteomic profiling by mass spectrometer	43	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 115	proteomic profiling by mass spectrometer	43	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 115	proteomic profiling by mass spectrometer	43	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 115	proteomic profiling by mass spectrometer	43	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 116	proteomic profiling by mass spectrometer	44	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 116	proteomic profiling by mass spectrometer	44	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 116	proteomic profiling by mass spectrometer	44	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 116	proteomic profiling by mass spectrometer	44	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 116	proteomic profiling by mass spectrometer	44	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 116	proteomic profiling by mass spectrometer	44	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 116	proteomic profiling by mass spectrometer	44	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 116	proteomic profiling by mass spectrometer	44	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 116	proteomic profiling by mass spectrometer	44	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 116	proteomic profiling by mass spectrometer	44	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 117	proteomic profiling by mass spectrometer	45	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 117	proteomic profiling by mass spectrometer	45	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 117	proteomic profiling by mass spectrometer	45	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 117	proteomic profiling by mass spectrometer	45	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 117	proteomic profiling by mass spectrometer	45	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 117	proteomic profiling by mass spectrometer	45	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 117	proteomic profiling by mass spectrometer	45	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 117	proteomic profiling by mass spectrometer	45	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 117	proteomic profiling by mass spectrometer	45	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 117	proteomic profiling by mass spectrometer	45	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 118	proteomic profiling by mass spectrometer	46	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 118	proteomic profiling by mass spectrometer	46	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 118	proteomic profiling by mass spectrometer	46	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 118	proteomic profiling by mass spectrometer	46	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 118	proteomic profiling by mass spectrometer	46	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 118	proteomic profiling by mass spectrometer	46	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 118	proteomic profiling by mass spectrometer	46	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 118	proteomic profiling by mass spectrometer	46	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 118	proteomic profiling by mass spectrometer	46	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 118	proteomic profiling by mass spectrometer	46	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 119	proteomic profiling by mass spectrometer	47	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 119	proteomic profiling by mass spectrometer	47	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 119	proteomic profiling by mass spectrometer	47	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 119	proteomic profiling by mass spectrometer	47	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 119	proteomic profiling by mass spectrometer	47	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 119	proteomic profiling by mass spectrometer	47	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 119	proteomic profiling by mass spectrometer	47	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 119	proteomic profiling by mass spectrometer	47	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 119	proteomic profiling by mass spectrometer	47	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 119	proteomic profiling by mass spectrometer	47	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 120	proteomic profiling by mass spectrometer	48	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 120	proteomic profiling by mass spectrometer	48	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 120	proteomic profiling by mass spectrometer	48	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 120	proteomic profiling by mass spectrometer	48	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 120	proteomic profiling by mass spectrometer	48	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 120	proteomic profiling by mass spectrometer	48	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 120	proteomic profiling by mass spectrometer	48	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 120	proteomic profiling by mass spectrometer	48	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 120	proteomic profiling by mass spectrometer	48	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 120	proteomic profiling by mass spectrometer	48	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 121	proteomic profiling by mass spectrometer	49	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 121	proteomic profiling by mass spectrometer	49	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 121	proteomic profiling by mass spectrometer	49	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 121	proteomic profiling by mass spectrometer	49	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 121	proteomic profiling by mass spectrometer	49	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 121	proteomic profiling by mass spectrometer	49	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 121	proteomic profiling by mass spectrometer	49	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 121	proteomic profiling by mass spectrometer	49	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 121	proteomic profiling by mass spectrometer	49	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 121	proteomic profiling by mass spectrometer	49	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 122	proteomic profiling by mass spectrometer	50	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 122	proteomic profiling by mass spectrometer	50	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 122	proteomic profiling by mass spectrometer	50	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 122	proteomic profiling by mass spectrometer	50	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 122	proteomic profiling by mass spectrometer	50	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 122	proteomic profiling by mass spectrometer	50	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 122	proteomic profiling by mass spectrometer	50	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 122	proteomic profiling by mass spectrometer	50	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 122	proteomic profiling by mass spectrometer	50	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 122	proteomic profiling by mass spectrometer	50	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 123	proteomic profiling by mass spectrometer	51	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 123	proteomic profiling by mass spectrometer	51	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 123	proteomic profiling by mass spectrometer	51	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 123	proteomic profiling by mass spectrometer	51	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 123	proteomic profiling by mass spectrometer	51	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 123	proteomic profiling by mass spectrometer	51	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 123	proteomic profiling by mass spectrometer	51	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 123	proteomic profiling by mass spectrometer	51	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 123	proteomic profiling by mass spectrometer	51	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 123	proteomic profiling by mass spectrometer	51	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 124	proteomic profiling by mass spectrometer	52	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 124	proteomic profiling by mass spectrometer	52	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 124	proteomic profiling by mass spectrometer	52	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 124	proteomic profiling by mass spectrometer	52	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 124	proteomic profiling by mass spectrometer	52	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 124	proteomic profiling by mass spectrometer	52	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 124	proteomic profiling by mass spectrometer	52	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 124	proteomic profiling by mass spectrometer	52	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 124	proteomic profiling by mass spectrometer	52	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 124	proteomic profiling by mass spectrometer	52	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 125	proteomic profiling by mass spectrometer	53	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 125	proteomic profiling by mass spectrometer	53	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 125	proteomic profiling by mass spectrometer	53	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 125	proteomic profiling by mass spectrometer	53	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 125	proteomic profiling by mass spectrometer	53	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 125	proteomic profiling by mass spectrometer	53	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 125	proteomic profiling by mass spectrometer	53	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 125	proteomic profiling by mass spectrometer	53	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 125	proteomic profiling by mass spectrometer	53	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 125	proteomic profiling by mass spectrometer	53	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 126	proteomic profiling by mass spectrometer	54	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 126	proteomic profiling by mass spectrometer	54	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 126	proteomic profiling by mass spectrometer	54	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 126	proteomic profiling by mass spectrometer	54	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 126	proteomic profiling by mass spectrometer	54	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 126	proteomic profiling by mass spectrometer	54	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 126	proteomic profiling by mass spectrometer	54	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 126	proteomic profiling by mass spectrometer	54	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 126	proteomic profiling by mass spectrometer	54	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 126	proteomic profiling by mass spectrometer	54	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 127	proteomic profiling by mass spectrometer	55	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 127	proteomic profiling by mass spectrometer	55	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 127	proteomic profiling by mass spectrometer	55	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 127	proteomic profiling by mass spectrometer	55	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 127	proteomic profiling by mass spectrometer	55	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 127	proteomic profiling by mass spectrometer	55	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 127	proteomic profiling by mass spectrometer	55	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 127	proteomic profiling by mass spectrometer	55	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 127	proteomic profiling by mass spectrometer	55	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 127	proteomic profiling by mass spectrometer	55	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 128	proteomic profiling by mass spectrometer	56	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 128	proteomic profiling by mass spectrometer	56	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 128	proteomic profiling by mass spectrometer	56	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 128	proteomic profiling by mass spectrometer	56	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 128	proteomic profiling by mass spectrometer	56	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 128	proteomic profiling by mass spectrometer	56	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 128	proteomic profiling by mass spectrometer	56	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 128	proteomic profiling by mass spectrometer	56	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 128	proteomic profiling by mass spectrometer	56	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 128	proteomic profiling by mass spectrometer	56	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 129	proteomic profiling by mass spectrometer	57	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 129	proteomic profiling by mass spectrometer	57	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 129	proteomic profiling by mass spectrometer	57	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 129	proteomic profiling by mass spectrometer	57	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 129	proteomic profiling by mass spectrometer	57	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 129	proteomic profiling by mass spectrometer	57	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 129	proteomic profiling by mass spectrometer	57	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 129	proteomic profiling by mass spectrometer	57	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 129	proteomic profiling by mass spectrometer	57	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 129	proteomic profiling by mass spectrometer	57	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 130	proteomic profiling by mass spectrometer	58	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 130	proteomic profiling by mass spectrometer	58	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 130	proteomic profiling by mass spectrometer	58	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 130	proteomic profiling by mass spectrometer	58	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 130	proteomic profiling by mass spectrometer	58	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 130	proteomic profiling by mass spectrometer	58	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 130	proteomic profiling by mass spectrometer	58	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 130	proteomic profiling by mass spectrometer	58	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 130	proteomic profiling by mass spectrometer	58	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 130	proteomic profiling by mass spectrometer	58	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 131	proteomic profiling by mass spectrometer	59	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 131	proteomic profiling by mass spectrometer	59	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 131	proteomic profiling by mass spectrometer	59	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 131	proteomic profiling by mass spectrometer	59	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 131	proteomic profiling by mass spectrometer	59	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 131	proteomic profiling by mass spectrometer	59	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 131	proteomic profiling by mass spectrometer	59	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 131	proteomic profiling by mass spectrometer	59	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 131	proteomic profiling by mass spectrometer	59	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 131	proteomic profiling by mass spectrometer	59	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 132	proteomic profiling by mass spectrometer	60	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 132	proteomic profiling by mass spectrometer	60	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 132	proteomic profiling by mass spectrometer	60	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 132	proteomic profiling by mass spectrometer	60	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 132	proteomic profiling by mass spectrometer	60	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 132	proteomic profiling by mass spectrometer	60	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 132	proteomic profiling by mass spectrometer	60	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 132	proteomic profiling by mass spectrometer	60	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 132	proteomic profiling by mass spectrometer	60	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 132	proteomic profiling by mass spectrometer	60	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 133	proteomic profiling by mass spectrometer	61	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 133	proteomic profiling by mass spectrometer	61	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 133	proteomic profiling by mass spectrometer	61	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 133	proteomic profiling by mass spectrometer	61	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 133	proteomic profiling by mass spectrometer	61	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 133	proteomic profiling by mass spectrometer	61	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 133	proteomic profiling by mass spectrometer	61	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 133	proteomic profiling by mass spectrometer	61	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 133	proteomic profiling by mass spectrometer	61	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 133	proteomic profiling by mass spectrometer	61	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 134	proteomic profiling by mass spectrometer	62	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 134	proteomic profiling by mass spectrometer	62	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 134	proteomic profiling by mass spectrometer	62	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 134	proteomic profiling by mass spectrometer	62	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 134	proteomic profiling by mass spectrometer	62	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 134	proteomic profiling by mass spectrometer	62	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 134	proteomic profiling by mass spectrometer	62	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 134	proteomic profiling by mass spectrometer	62	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 134	proteomic profiling by mass spectrometer	62	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 134	proteomic profiling by mass spectrometer	62	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 135	proteomic profiling by mass spectrometer	63	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 135	proteomic profiling by mass spectrometer	63	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 135	proteomic profiling by mass spectrometer	63	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 135	proteomic profiling by mass spectrometer	63	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 135	proteomic profiling by mass spectrometer	63	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 135	proteomic profiling by mass spectrometer	63	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 135	proteomic profiling by mass spectrometer	63	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 135	proteomic profiling by mass spectrometer	63	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 135	proteomic profiling by mass spectrometer	63	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 135	proteomic profiling by mass spectrometer	63	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 136	proteomic profiling by mass spectrometer	64	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 136	proteomic profiling by mass spectrometer	64	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 136	proteomic profiling by mass spectrometer	64	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 136	proteomic profiling by mass spectrometer	64	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 136	proteomic profiling by mass spectrometer	64	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 136	proteomic profiling by mass spectrometer	64	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 136	proteomic profiling by mass spectrometer	64	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 136	proteomic profiling by mass spectrometer	64	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 136	proteomic profiling by mass spectrometer	64	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 136	proteomic profiling by mass spectrometer	64	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 137	proteomic profiling by mass spectrometer	65	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 137	proteomic profiling by mass spectrometer	65	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 137	proteomic profiling by mass spectrometer	65	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 137	proteomic profiling by mass spectrometer	65	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 137	proteomic profiling by mass spectrometer	65	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 137	proteomic profiling by mass spectrometer	65	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 137	proteomic profiling by mass spectrometer	65	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 137	proteomic profiling by mass spectrometer	65	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 137	proteomic profiling by mass spectrometer	65	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 137	proteomic profiling by mass spectrometer	65	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 138	proteomic profiling by mass spectrometer	66	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 138	proteomic profiling by mass spectrometer	66	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 138	proteomic profiling by mass spectrometer	66	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 138	proteomic profiling by mass spectrometer	66	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 138	proteomic profiling by mass spectrometer	66	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 138	proteomic profiling by mass spectrometer	66	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 138	proteomic profiling by mass spectrometer	66	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 138	proteomic profiling by mass spectrometer	66	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 138	proteomic profiling by mass spectrometer	66	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 138	proteomic profiling by mass spectrometer	66	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 139	proteomic profiling by mass spectrometer	67	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 139	proteomic profiling by mass spectrometer	67	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 139	proteomic profiling by mass spectrometer	67	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 139	proteomic profiling by mass spectrometer	67	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 139	proteomic profiling by mass spectrometer	67	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 139	proteomic profiling by mass spectrometer	67	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 139	proteomic profiling by mass spectrometer	67	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 139	proteomic profiling by mass spectrometer	67	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 139	proteomic profiling by mass spectrometer	67	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 139	proteomic profiling by mass spectrometer	67	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 140	proteomic profiling by mass spectrometer	68	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 140	proteomic profiling by mass spectrometer	68	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 140	proteomic profiling by mass spectrometer	68	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 140	proteomic profiling by mass spectrometer	68	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 140	proteomic profiling by mass spectrometer	68	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 140	proteomic profiling by mass spectrometer	68	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 140	proteomic profiling by mass spectrometer	68	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 140	proteomic profiling by mass spectrometer	68	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 140	proteomic profiling by mass spectrometer	68	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 140	proteomic profiling by mass spectrometer	68	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 141	proteomic profiling by mass spectrometer	69	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 141	proteomic profiling by mass spectrometer	69	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 141	proteomic profiling by mass spectrometer	69	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 141	proteomic profiling by mass spectrometer	69	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 141	proteomic profiling by mass spectrometer	69	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 141	proteomic profiling by mass spectrometer	69	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 141	proteomic profiling by mass spectrometer	69	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 141	proteomic profiling by mass spectrometer	69	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 141	proteomic profiling by mass spectrometer	69	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 141	proteomic profiling by mass spectrometer	69	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 142	proteomic profiling by mass spectrometer	70	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 142	proteomic profiling by mass spectrometer	70	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 142	proteomic profiling by mass spectrometer	70	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 142	proteomic profiling by mass spectrometer	70	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 142	proteomic profiling by mass spectrometer	70	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 142	proteomic profiling by mass spectrometer	70	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 142	proteomic profiling by mass spectrometer	70	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 142	proteomic profiling by mass spectrometer	70	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 142	proteomic profiling by mass spectrometer	70	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 142	proteomic profiling by mass spectrometer	70	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 143	proteomic profiling by mass spectrometer	71	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 143	proteomic profiling by mass spectrometer	71	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 143	proteomic profiling by mass spectrometer	71	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 143	proteomic profiling by mass spectrometer	71	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 143	proteomic profiling by mass spectrometer	71	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 143	proteomic profiling by mass spectrometer	71	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 143	proteomic profiling by mass spectrometer	71	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 143	proteomic profiling by mass spectrometer	71	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 143	proteomic profiling by mass spectrometer	71	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 143	proteomic profiling by mass spectrometer	71	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	run 144	proteomic profiling by mass spectrometer	72	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	run 144	proteomic profiling by mass spectrometer	72	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	run 144	proteomic profiling by mass spectrometer	72	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	run 144	proteomic profiling by mass spectrometer	72	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	run 144	proteomic profiling by mass spectrometer	72	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	run 144	proteomic profiling by mass spectrometer	72	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	run 144	proteomic profiling by mass spectrometer	72	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	run 144	proteomic profiling by mass spectrometer	72	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	run 144	proteomic profiling by mass spectrometer	72	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	run 144	proteomic profiling by mass spectrometer	72	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 145	proteomic profiling by mass spectrometer	1	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 145	proteomic profiling by mass spectrometer	1	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 145	proteomic profiling by mass spectrometer	1	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 145	proteomic profiling by mass spectrometer	1	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 145	proteomic profiling by mass spectrometer	1	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 145	proteomic profiling by mass spectrometer	1	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 145	proteomic profiling by mass spectrometer	1	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 145	proteomic profiling by mass spectrometer	1	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 145	proteomic profiling by mass spectrometer	1	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 145	proteomic profiling by mass spectrometer	1	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 146	proteomic profiling by mass spectrometer	2	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 146	proteomic profiling by mass spectrometer	2	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 146	proteomic profiling by mass spectrometer	2	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 146	proteomic profiling by mass spectrometer	2	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 146	proteomic profiling by mass spectrometer	2	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 146	proteomic profiling by mass spectrometer	2	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 146	proteomic profiling by mass spectrometer	2	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 146	proteomic profiling by mass spectrometer	2	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 146	proteomic profiling by mass spectrometer	2	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 146	proteomic profiling by mass spectrometer	2	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 147	proteomic profiling by mass spectrometer	3	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 147	proteomic profiling by mass spectrometer	3	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 147	proteomic profiling by mass spectrometer	3	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 147	proteomic profiling by mass spectrometer	3	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 147	proteomic profiling by mass spectrometer	3	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 147	proteomic profiling by mass spectrometer	3	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 147	proteomic profiling by mass spectrometer	3	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 147	proteomic profiling by mass spectrometer	3	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 147	proteomic profiling by mass spectrometer	3	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 147	proteomic profiling by mass spectrometer	3	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 148	proteomic profiling by mass spectrometer	4	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 148	proteomic profiling by mass spectrometer	4	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 148	proteomic profiling by mass spectrometer	4	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 148	proteomic profiling by mass spectrometer	4	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 148	proteomic profiling by mass spectrometer	4	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 148	proteomic profiling by mass spectrometer	4	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 148	proteomic profiling by mass spectrometer	4	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 148	proteomic profiling by mass spectrometer	4	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 148	proteomic profiling by mass spectrometer	4	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 148	proteomic profiling by mass spectrometer	4	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 149	proteomic profiling by mass spectrometer	5	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 149	proteomic profiling by mass spectrometer	5	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 149	proteomic profiling by mass spectrometer	5	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 149	proteomic profiling by mass spectrometer	5	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 149	proteomic profiling by mass spectrometer	5	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 149	proteomic profiling by mass spectrometer	5	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 149	proteomic profiling by mass spectrometer	5	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 149	proteomic profiling by mass spectrometer	5	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 149	proteomic profiling by mass spectrometer	5	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 149	proteomic profiling by mass spectrometer	5	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 150	proteomic profiling by mass spectrometer	6	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 150	proteomic profiling by mass spectrometer	6	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 150	proteomic profiling by mass spectrometer	6	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 150	proteomic profiling by mass spectrometer	6	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 150	proteomic profiling by mass spectrometer	6	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 150	proteomic profiling by mass spectrometer	6	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 150	proteomic profiling by mass spectrometer	6	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 150	proteomic profiling by mass spectrometer	6	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 150	proteomic profiling by mass spectrometer	6	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 150	proteomic profiling by mass spectrometer	6	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 151	proteomic profiling by mass spectrometer	7	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 151	proteomic profiling by mass spectrometer	7	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 151	proteomic profiling by mass spectrometer	7	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 151	proteomic profiling by mass spectrometer	7	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 151	proteomic profiling by mass spectrometer	7	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 151	proteomic profiling by mass spectrometer	7	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 151	proteomic profiling by mass spectrometer	7	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 151	proteomic profiling by mass spectrometer	7	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 151	proteomic profiling by mass spectrometer	7	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 151	proteomic profiling by mass spectrometer	7	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 152	proteomic profiling by mass spectrometer	8	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 152	proteomic profiling by mass spectrometer	8	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 152	proteomic profiling by mass spectrometer	8	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 152	proteomic profiling by mass spectrometer	8	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 152	proteomic profiling by mass spectrometer	8	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 152	proteomic profiling by mass spectrometer	8	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 152	proteomic profiling by mass spectrometer	8	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 152	proteomic profiling by mass spectrometer	8	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 152	proteomic profiling by mass spectrometer	8	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 152	proteomic profiling by mass spectrometer	8	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 153	proteomic profiling by mass spectrometer	9	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 153	proteomic profiling by mass spectrometer	9	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 153	proteomic profiling by mass spectrometer	9	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 153	proteomic profiling by mass spectrometer	9	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 153	proteomic profiling by mass spectrometer	9	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 153	proteomic profiling by mass spectrometer	9	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 153	proteomic profiling by mass spectrometer	9	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 153	proteomic profiling by mass spectrometer	9	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 153	proteomic profiling by mass spectrometer	9	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 153	proteomic profiling by mass spectrometer	9	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 154	proteomic profiling by mass spectrometer	10	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 154	proteomic profiling by mass spectrometer	10	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 154	proteomic profiling by mass spectrometer	10	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 154	proteomic profiling by mass spectrometer	10	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 154	proteomic profiling by mass spectrometer	10	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 154	proteomic profiling by mass spectrometer	10	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 154	proteomic profiling by mass spectrometer	10	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 154	proteomic profiling by mass spectrometer	10	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 154	proteomic profiling by mass spectrometer	10	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 154	proteomic profiling by mass spectrometer	10	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 155	proteomic profiling by mass spectrometer	11	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 155	proteomic profiling by mass spectrometer	11	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 155	proteomic profiling by mass spectrometer	11	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 155	proteomic profiling by mass spectrometer	11	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 155	proteomic profiling by mass spectrometer	11	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 155	proteomic profiling by mass spectrometer	11	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 155	proteomic profiling by mass spectrometer	11	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 155	proteomic profiling by mass spectrometer	11	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 155	proteomic profiling by mass spectrometer	11	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 155	proteomic profiling by mass spectrometer	11	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 156	proteomic profiling by mass spectrometer	12	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 156	proteomic profiling by mass spectrometer	12	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 156	proteomic profiling by mass spectrometer	12	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 156	proteomic profiling by mass spectrometer	12	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 156	proteomic profiling by mass spectrometer	12	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 156	proteomic profiling by mass spectrometer	12	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 156	proteomic profiling by mass spectrometer	12	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 156	proteomic profiling by mass spectrometer	12	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 156	proteomic profiling by mass spectrometer	12	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 156	proteomic profiling by mass spectrometer	12	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 157	proteomic profiling by mass spectrometer	13	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 157	proteomic profiling by mass spectrometer	13	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 157	proteomic profiling by mass spectrometer	13	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 157	proteomic profiling by mass spectrometer	13	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 157	proteomic profiling by mass spectrometer	13	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 157	proteomic profiling by mass spectrometer	13	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 157	proteomic profiling by mass spectrometer	13	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 157	proteomic profiling by mass spectrometer	13	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 157	proteomic profiling by mass spectrometer	13	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 157	proteomic profiling by mass spectrometer	13	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 158	proteomic profiling by mass spectrometer	14	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 158	proteomic profiling by mass spectrometer	14	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 158	proteomic profiling by mass spectrometer	14	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 158	proteomic profiling by mass spectrometer	14	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 158	proteomic profiling by mass spectrometer	14	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 158	proteomic profiling by mass spectrometer	14	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 158	proteomic profiling by mass spectrometer	14	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 158	proteomic profiling by mass spectrometer	14	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 158	proteomic profiling by mass spectrometer	14	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 158	proteomic profiling by mass spectrometer	14	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 159	proteomic profiling by mass spectrometer	15	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 159	proteomic profiling by mass spectrometer	15	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 159	proteomic profiling by mass spectrometer	15	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 159	proteomic profiling by mass spectrometer	15	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 159	proteomic profiling by mass spectrometer	15	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 159	proteomic profiling by mass spectrometer	15	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 159	proteomic profiling by mass spectrometer	15	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 159	proteomic profiling by mass spectrometer	15	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 159	proteomic profiling by mass spectrometer	15	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 159	proteomic profiling by mass spectrometer	15	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 160	proteomic profiling by mass spectrometer	16	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 160	proteomic profiling by mass spectrometer	16	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 160	proteomic profiling by mass spectrometer	16	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 160	proteomic profiling by mass spectrometer	16	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 160	proteomic profiling by mass spectrometer	16	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 160	proteomic profiling by mass spectrometer	16	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 160	proteomic profiling by mass spectrometer	16	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 160	proteomic profiling by mass spectrometer	16	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 160	proteomic profiling by mass spectrometer	16	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 160	proteomic profiling by mass spectrometer	16	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 161	proteomic profiling by mass spectrometer	17	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 161	proteomic profiling by mass spectrometer	17	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 161	proteomic profiling by mass spectrometer	17	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 161	proteomic profiling by mass spectrometer	17	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 161	proteomic profiling by mass spectrometer	17	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 161	proteomic profiling by mass spectrometer	17	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 161	proteomic profiling by mass spectrometer	17	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 161	proteomic profiling by mass spectrometer	17	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 161	proteomic profiling by mass spectrometer	17	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 161	proteomic profiling by mass spectrometer	17	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 162	proteomic profiling by mass spectrometer	18	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 162	proteomic profiling by mass spectrometer	18	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 162	proteomic profiling by mass spectrometer	18	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 162	proteomic profiling by mass spectrometer	18	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 162	proteomic profiling by mass spectrometer	18	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 162	proteomic profiling by mass spectrometer	18	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 162	proteomic profiling by mass spectrometer	18	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 162	proteomic profiling by mass spectrometer	18	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 162	proteomic profiling by mass spectrometer	18	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 162	proteomic profiling by mass spectrometer	18	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 163	proteomic profiling by mass spectrometer	19	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 163	proteomic profiling by mass spectrometer	19	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 163	proteomic profiling by mass spectrometer	19	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 163	proteomic profiling by mass spectrometer	19	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 163	proteomic profiling by mass spectrometer	19	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 163	proteomic profiling by mass spectrometer	19	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 163	proteomic profiling by mass spectrometer	19	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 163	proteomic profiling by mass spectrometer	19	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 163	proteomic profiling by mass spectrometer	19	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 163	proteomic profiling by mass spectrometer	19	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 164	proteomic profiling by mass spectrometer	20	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 164	proteomic profiling by mass spectrometer	20	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 164	proteomic profiling by mass spectrometer	20	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 164	proteomic profiling by mass spectrometer	20	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 164	proteomic profiling by mass spectrometer	20	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 164	proteomic profiling by mass spectrometer	20	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 164	proteomic profiling by mass spectrometer	20	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 164	proteomic profiling by mass spectrometer	20	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 164	proteomic profiling by mass spectrometer	20	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 164	proteomic profiling by mass spectrometer	20	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 165	proteomic profiling by mass spectrometer	21	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 165	proteomic profiling by mass spectrometer	21	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 165	proteomic profiling by mass spectrometer	21	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 165	proteomic profiling by mass spectrometer	21	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 165	proteomic profiling by mass spectrometer	21	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 165	proteomic profiling by mass spectrometer	21	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 165	proteomic profiling by mass spectrometer	21	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 165	proteomic profiling by mass spectrometer	21	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 165	proteomic profiling by mass spectrometer	21	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 165	proteomic profiling by mass spectrometer	21	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 166	proteomic profiling by mass spectrometer	22	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 166	proteomic profiling by mass spectrometer	22	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 166	proteomic profiling by mass spectrometer	22	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 166	proteomic profiling by mass spectrometer	22	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 166	proteomic profiling by mass spectrometer	22	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 166	proteomic profiling by mass spectrometer	22	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 166	proteomic profiling by mass spectrometer	22	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 166	proteomic profiling by mass spectrometer	22	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 166	proteomic profiling by mass spectrometer	22	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 166	proteomic profiling by mass spectrometer	22	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 167	proteomic profiling by mass spectrometer	23	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 167	proteomic profiling by mass spectrometer	23	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 167	proteomic profiling by mass spectrometer	23	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 167	proteomic profiling by mass spectrometer	23	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 167	proteomic profiling by mass spectrometer	23	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 167	proteomic profiling by mass spectrometer	23	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 167	proteomic profiling by mass spectrometer	23	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 167	proteomic profiling by mass spectrometer	23	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 167	proteomic profiling by mass spectrometer	23	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 167	proteomic profiling by mass spectrometer	23	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 168	proteomic profiling by mass spectrometer	24	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 168	proteomic profiling by mass spectrometer	24	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 168	proteomic profiling by mass spectrometer	24	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 168	proteomic profiling by mass spectrometer	24	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 168	proteomic profiling by mass spectrometer	24	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 168	proteomic profiling by mass spectrometer	24	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 168	proteomic profiling by mass spectrometer	24	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 168	proteomic profiling by mass spectrometer	24	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 168	proteomic profiling by mass spectrometer	24	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 168	proteomic profiling by mass spectrometer	24	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 169	proteomic profiling by mass spectrometer	25	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 169	proteomic profiling by mass spectrometer	25	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 169	proteomic profiling by mass spectrometer	25	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 169	proteomic profiling by mass spectrometer	25	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 169	proteomic profiling by mass spectrometer	25	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 169	proteomic profiling by mass spectrometer	25	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 169	proteomic profiling by mass spectrometer	25	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 169	proteomic profiling by mass spectrometer	25	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 169	proteomic profiling by mass spectrometer	25	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 169	proteomic profiling by mass spectrometer	25	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 170	proteomic profiling by mass spectrometer	26	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 170	proteomic profiling by mass spectrometer	26	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 170	proteomic profiling by mass spectrometer	26	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 170	proteomic profiling by mass spectrometer	26	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 170	proteomic profiling by mass spectrometer	26	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 170	proteomic profiling by mass spectrometer	26	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 170	proteomic profiling by mass spectrometer	26	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 170	proteomic profiling by mass spectrometer	26	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 170	proteomic profiling by mass spectrometer	26	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 170	proteomic profiling by mass spectrometer	26	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 171	proteomic profiling by mass spectrometer	27	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 171	proteomic profiling by mass spectrometer	27	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 171	proteomic profiling by mass spectrometer	27	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 171	proteomic profiling by mass spectrometer	27	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 171	proteomic profiling by mass spectrometer	27	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 171	proteomic profiling by mass spectrometer	27	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 171	proteomic profiling by mass spectrometer	27	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 171	proteomic profiling by mass spectrometer	27	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 171	proteomic profiling by mass spectrometer	27	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 171	proteomic profiling by mass spectrometer	27	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 172	proteomic profiling by mass spectrometer	28	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 172	proteomic profiling by mass spectrometer	28	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 172	proteomic profiling by mass spectrometer	28	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 172	proteomic profiling by mass spectrometer	28	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 172	proteomic profiling by mass spectrometer	28	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 172	proteomic profiling by mass spectrometer	28	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 172	proteomic profiling by mass spectrometer	28	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 172	proteomic profiling by mass spectrometer	28	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 172	proteomic profiling by mass spectrometer	28	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 172	proteomic profiling by mass spectrometer	28	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 173	proteomic profiling by mass spectrometer	29	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 173	proteomic profiling by mass spectrometer	29	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 173	proteomic profiling by mass spectrometer	29	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 173	proteomic profiling by mass spectrometer	29	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 173	proteomic profiling by mass spectrometer	29	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 173	proteomic profiling by mass spectrometer	29	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 173	proteomic profiling by mass spectrometer	29	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 173	proteomic profiling by mass spectrometer	29	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 173	proteomic profiling by mass spectrometer	29	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 173	proteomic profiling by mass spectrometer	29	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 174	proteomic profiling by mass spectrometer	30	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 174	proteomic profiling by mass spectrometer	30	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 174	proteomic profiling by mass spectrometer	30	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 174	proteomic profiling by mass spectrometer	30	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 174	proteomic profiling by mass spectrometer	30	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 174	proteomic profiling by mass spectrometer	30	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 174	proteomic profiling by mass spectrometer	30	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 174	proteomic profiling by mass spectrometer	30	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 174	proteomic profiling by mass spectrometer	30	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 174	proteomic profiling by mass spectrometer	30	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 175	proteomic profiling by mass spectrometer	31	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 175	proteomic profiling by mass spectrometer	31	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 175	proteomic profiling by mass spectrometer	31	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 175	proteomic profiling by mass spectrometer	31	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 175	proteomic profiling by mass spectrometer	31	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 175	proteomic profiling by mass spectrometer	31	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 175	proteomic profiling by mass spectrometer	31	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 175	proteomic profiling by mass spectrometer	31	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 175	proteomic profiling by mass spectrometer	31	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 175	proteomic profiling by mass spectrometer	31	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 176	proteomic profiling by mass spectrometer	32	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 176	proteomic profiling by mass spectrometer	32	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 176	proteomic profiling by mass spectrometer	32	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 176	proteomic profiling by mass spectrometer	32	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 176	proteomic profiling by mass spectrometer	32	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 176	proteomic profiling by mass spectrometer	32	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 176	proteomic profiling by mass spectrometer	32	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 176	proteomic profiling by mass spectrometer	32	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 176	proteomic profiling by mass spectrometer	32	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 176	proteomic profiling by mass spectrometer	32	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 177	proteomic profiling by mass spectrometer	33	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 177	proteomic profiling by mass spectrometer	33	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 177	proteomic profiling by mass spectrometer	33	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 177	proteomic profiling by mass spectrometer	33	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 177	proteomic profiling by mass spectrometer	33	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 177	proteomic profiling by mass spectrometer	33	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 177	proteomic profiling by mass spectrometer	33	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 177	proteomic profiling by mass spectrometer	33	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 177	proteomic profiling by mass spectrometer	33	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 177	proteomic profiling by mass spectrometer	33	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 178	proteomic profiling by mass spectrometer	34	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 178	proteomic profiling by mass spectrometer	34	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 178	proteomic profiling by mass spectrometer	34	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 178	proteomic profiling by mass spectrometer	34	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 178	proteomic profiling by mass spectrometer	34	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 178	proteomic profiling by mass spectrometer	34	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 178	proteomic profiling by mass spectrometer	34	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 178	proteomic profiling by mass spectrometer	34	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 178	proteomic profiling by mass spectrometer	34	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 178	proteomic profiling by mass spectrometer	34	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 179	proteomic profiling by mass spectrometer	35	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 179	proteomic profiling by mass spectrometer	35	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 179	proteomic profiling by mass spectrometer	35	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 179	proteomic profiling by mass spectrometer	35	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 179	proteomic profiling by mass spectrometer	35	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 179	proteomic profiling by mass spectrometer	35	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 179	proteomic profiling by mass spectrometer	35	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 179	proteomic profiling by mass spectrometer	35	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 179	proteomic profiling by mass spectrometer	35	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 179	proteomic profiling by mass spectrometer	35	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 180	proteomic profiling by mass spectrometer	36	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 180	proteomic profiling by mass spectrometer	36	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 180	proteomic profiling by mass spectrometer	36	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 180	proteomic profiling by mass spectrometer	36	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 180	proteomic profiling by mass spectrometer	36	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 180	proteomic profiling by mass spectrometer	36	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 180	proteomic profiling by mass spectrometer	36	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 180	proteomic profiling by mass spectrometer	36	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 180	proteomic profiling by mass spectrometer	36	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 180	proteomic profiling by mass spectrometer	36	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 181	proteomic profiling by mass spectrometer	37	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 181	proteomic profiling by mass spectrometer	37	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 181	proteomic profiling by mass spectrometer	37	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 181	proteomic profiling by mass spectrometer	37	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 181	proteomic profiling by mass spectrometer	37	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 181	proteomic profiling by mass spectrometer	37	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 181	proteomic profiling by mass spectrometer	37	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 181	proteomic profiling by mass spectrometer	37	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 181	proteomic profiling by mass spectrometer	37	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 181	proteomic profiling by mass spectrometer	37	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 182	proteomic profiling by mass spectrometer	38	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 182	proteomic profiling by mass spectrometer	38	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 182	proteomic profiling by mass spectrometer	38	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 182	proteomic profiling by mass spectrometer	38	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 182	proteomic profiling by mass spectrometer	38	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 182	proteomic profiling by mass spectrometer	38	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 182	proteomic profiling by mass spectrometer	38	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 182	proteomic profiling by mass spectrometer	38	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 182	proteomic profiling by mass spectrometer	38	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 182	proteomic profiling by mass spectrometer	38	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 183	proteomic profiling by mass spectrometer	39	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 183	proteomic profiling by mass spectrometer	39	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 183	proteomic profiling by mass spectrometer	39	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 183	proteomic profiling by mass spectrometer	39	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 183	proteomic profiling by mass spectrometer	39	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 183	proteomic profiling by mass spectrometer	39	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 183	proteomic profiling by mass spectrometer	39	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 183	proteomic profiling by mass spectrometer	39	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 183	proteomic profiling by mass spectrometer	39	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 183	proteomic profiling by mass spectrometer	39	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 184	proteomic profiling by mass spectrometer	40	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 184	proteomic profiling by mass spectrometer	40	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 184	proteomic profiling by mass spectrometer	40	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 184	proteomic profiling by mass spectrometer	40	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 184	proteomic profiling by mass spectrometer	40	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 184	proteomic profiling by mass spectrometer	40	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 184	proteomic profiling by mass spectrometer	40	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 184	proteomic profiling by mass spectrometer	40	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 184	proteomic profiling by mass spectrometer	40	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 184	proteomic profiling by mass spectrometer	40	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 185	proteomic profiling by mass spectrometer	41	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 185	proteomic profiling by mass spectrometer	41	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 185	proteomic profiling by mass spectrometer	41	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 185	proteomic profiling by mass spectrometer	41	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 185	proteomic profiling by mass spectrometer	41	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 185	proteomic profiling by mass spectrometer	41	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 185	proteomic profiling by mass spectrometer	41	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 185	proteomic profiling by mass spectrometer	41	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 185	proteomic profiling by mass spectrometer	41	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 185	proteomic profiling by mass spectrometer	41	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 186	proteomic profiling by mass spectrometer	42	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 186	proteomic profiling by mass spectrometer	42	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 186	proteomic profiling by mass spectrometer	42	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 186	proteomic profiling by mass spectrometer	42	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 186	proteomic profiling by mass spectrometer	42	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 186	proteomic profiling by mass spectrometer	42	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 186	proteomic profiling by mass spectrometer	42	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 186	proteomic profiling by mass spectrometer	42	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 186	proteomic profiling by mass spectrometer	42	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 186	proteomic profiling by mass spectrometer	42	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 187	proteomic profiling by mass spectrometer	43	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 187	proteomic profiling by mass spectrometer	43	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 187	proteomic profiling by mass spectrometer	43	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 187	proteomic profiling by mass spectrometer	43	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 187	proteomic profiling by mass spectrometer	43	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 187	proteomic profiling by mass spectrometer	43	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 187	proteomic profiling by mass spectrometer	43	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 187	proteomic profiling by mass spectrometer	43	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 187	proteomic profiling by mass spectrometer	43	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 187	proteomic profiling by mass spectrometer	43	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 188	proteomic profiling by mass spectrometer	44	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 188	proteomic profiling by mass spectrometer	44	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 188	proteomic profiling by mass spectrometer	44	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 188	proteomic profiling by mass spectrometer	44	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 188	proteomic profiling by mass spectrometer	44	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 188	proteomic profiling by mass spectrometer	44	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 188	proteomic profiling by mass spectrometer	44	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 188	proteomic profiling by mass spectrometer	44	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 188	proteomic profiling by mass spectrometer	44	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 188	proteomic profiling by mass spectrometer	44	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 189	proteomic profiling by mass spectrometer	45	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 189	proteomic profiling by mass spectrometer	45	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 189	proteomic profiling by mass spectrometer	45	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 189	proteomic profiling by mass spectrometer	45	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 189	proteomic profiling by mass spectrometer	45	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 189	proteomic profiling by mass spectrometer	45	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 189	proteomic profiling by mass spectrometer	45	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 189	proteomic profiling by mass spectrometer	45	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 189	proteomic profiling by mass spectrometer	45	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 189	proteomic profiling by mass spectrometer	45	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 190	proteomic profiling by mass spectrometer	46	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 190	proteomic profiling by mass spectrometer	46	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 190	proteomic profiling by mass spectrometer	46	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 190	proteomic profiling by mass spectrometer	46	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 190	proteomic profiling by mass spectrometer	46	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 190	proteomic profiling by mass spectrometer	46	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 190	proteomic profiling by mass spectrometer	46	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 190	proteomic profiling by mass spectrometer	46	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 190	proteomic profiling by mass spectrometer	46	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 190	proteomic profiling by mass spectrometer	46	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 191	proteomic profiling by mass spectrometer	47	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 191	proteomic profiling by mass spectrometer	47	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 191	proteomic profiling by mass spectrometer	47	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 191	proteomic profiling by mass spectrometer	47	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 191	proteomic profiling by mass spectrometer	47	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 191	proteomic profiling by mass spectrometer	47	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 191	proteomic profiling by mass spectrometer	47	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 191	proteomic profiling by mass spectrometer	47	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 191	proteomic profiling by mass spectrometer	47	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 191	proteomic profiling by mass spectrometer	47	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 192	proteomic profiling by mass spectrometer	48	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 192	proteomic profiling by mass spectrometer	48	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 192	proteomic profiling by mass spectrometer	48	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 192	proteomic profiling by mass spectrometer	48	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 192	proteomic profiling by mass spectrometer	48	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 192	proteomic profiling by mass spectrometer	48	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 192	proteomic profiling by mass spectrometer	48	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 192	proteomic profiling by mass spectrometer	48	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 192	proteomic profiling by mass spectrometer	48	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 192	proteomic profiling by mass spectrometer	48	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 193	proteomic profiling by mass spectrometer	49	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 193	proteomic profiling by mass spectrometer	49	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 193	proteomic profiling by mass spectrometer	49	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 193	proteomic profiling by mass spectrometer	49	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 193	proteomic profiling by mass spectrometer	49	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 193	proteomic profiling by mass spectrometer	49	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 193	proteomic profiling by mass spectrometer	49	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 193	proteomic profiling by mass spectrometer	49	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 193	proteomic profiling by mass spectrometer	49	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 193	proteomic profiling by mass spectrometer	49	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 194	proteomic profiling by mass spectrometer	50	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 194	proteomic profiling by mass spectrometer	50	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 194	proteomic profiling by mass spectrometer	50	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 194	proteomic profiling by mass spectrometer	50	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 194	proteomic profiling by mass spectrometer	50	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 194	proteomic profiling by mass spectrometer	50	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 194	proteomic profiling by mass spectrometer	50	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 194	proteomic profiling by mass spectrometer	50	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 194	proteomic profiling by mass spectrometer	50	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 194	proteomic profiling by mass spectrometer	50	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 195	proteomic profiling by mass spectrometer	51	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 195	proteomic profiling by mass spectrometer	51	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 195	proteomic profiling by mass spectrometer	51	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 195	proteomic profiling by mass spectrometer	51	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 195	proteomic profiling by mass spectrometer	51	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 195	proteomic profiling by mass spectrometer	51	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 195	proteomic profiling by mass spectrometer	51	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 195	proteomic profiling by mass spectrometer	51	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 195	proteomic profiling by mass spectrometer	51	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 195	proteomic profiling by mass spectrometer	51	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 196	proteomic profiling by mass spectrometer	52	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 196	proteomic profiling by mass spectrometer	52	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 196	proteomic profiling by mass spectrometer	52	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 196	proteomic profiling by mass spectrometer	52	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 196	proteomic profiling by mass spectrometer	52	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 196	proteomic profiling by mass spectrometer	52	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 196	proteomic profiling by mass spectrometer	52	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 196	proteomic profiling by mass spectrometer	52	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 196	proteomic profiling by mass spectrometer	52	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 196	proteomic profiling by mass spectrometer	52	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 197	proteomic profiling by mass spectrometer	53	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 197	proteomic profiling by mass spectrometer	53	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 197	proteomic profiling by mass spectrometer	53	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 197	proteomic profiling by mass spectrometer	53	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 197	proteomic profiling by mass spectrometer	53	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 197	proteomic profiling by mass spectrometer	53	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 197	proteomic profiling by mass spectrometer	53	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 197	proteomic profiling by mass spectrometer	53	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 197	proteomic profiling by mass spectrometer	53	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 197	proteomic profiling by mass spectrometer	53	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 198	proteomic profiling by mass spectrometer	54	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 198	proteomic profiling by mass spectrometer	54	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 198	proteomic profiling by mass spectrometer	54	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 198	proteomic profiling by mass spectrometer	54	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 198	proteomic profiling by mass spectrometer	54	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 198	proteomic profiling by mass spectrometer	54	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 198	proteomic profiling by mass spectrometer	54	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 198	proteomic profiling by mass spectrometer	54	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 198	proteomic profiling by mass spectrometer	54	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 198	proteomic profiling by mass spectrometer	54	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 199	proteomic profiling by mass spectrometer	55	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 199	proteomic profiling by mass spectrometer	55	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 199	proteomic profiling by mass spectrometer	55	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 199	proteomic profiling by mass spectrometer	55	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 199	proteomic profiling by mass spectrometer	55	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 199	proteomic profiling by mass spectrometer	55	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 199	proteomic profiling by mass spectrometer	55	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 199	proteomic profiling by mass spectrometer	55	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 199	proteomic profiling by mass spectrometer	55	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 199	proteomic profiling by mass spectrometer	55	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 200	proteomic profiling by mass spectrometer	56	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 200	proteomic profiling by mass spectrometer	56	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 200	proteomic profiling by mass spectrometer	56	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 200	proteomic profiling by mass spectrometer	56	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 200	proteomic profiling by mass spectrometer	56	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 200	proteomic profiling by mass spectrometer	56	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 200	proteomic profiling by mass spectrometer	56	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 200	proteomic profiling by mass spectrometer	56	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 200	proteomic profiling by mass spectrometer	56	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 200	proteomic profiling by mass spectrometer	56	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 201	proteomic profiling by mass spectrometer	57	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 201	proteomic profiling by mass spectrometer	57	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 201	proteomic profiling by mass spectrometer	57	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 201	proteomic profiling by mass spectrometer	57	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 201	proteomic profiling by mass spectrometer	57	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 201	proteomic profiling by mass spectrometer	57	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 201	proteomic profiling by mass spectrometer	57	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 201	proteomic profiling by mass spectrometer	57	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 201	proteomic profiling by mass spectrometer	57	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 201	proteomic profiling by mass spectrometer	57	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 202	proteomic profiling by mass spectrometer	58	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 202	proteomic profiling by mass spectrometer	58	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 202	proteomic profiling by mass spectrometer	58	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 202	proteomic profiling by mass spectrometer	58	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 202	proteomic profiling by mass spectrometer	58	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 202	proteomic profiling by mass spectrometer	58	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 202	proteomic profiling by mass spectrometer	58	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 202	proteomic profiling by mass spectrometer	58	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 202	proteomic profiling by mass spectrometer	58	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 202	proteomic profiling by mass spectrometer	58	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 203	proteomic profiling by mass spectrometer	59	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 203	proteomic profiling by mass spectrometer	59	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 203	proteomic profiling by mass spectrometer	59	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 203	proteomic profiling by mass spectrometer	59	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 203	proteomic profiling by mass spectrometer	59	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 203	proteomic profiling by mass spectrometer	59	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 203	proteomic profiling by mass spectrometer	59	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 203	proteomic profiling by mass spectrometer	59	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 203	proteomic profiling by mass spectrometer	59	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 203	proteomic profiling by mass spectrometer	59	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 204	proteomic profiling by mass spectrometer	60	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 204	proteomic profiling by mass spectrometer	60	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 204	proteomic profiling by mass spectrometer	60	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 204	proteomic profiling by mass spectrometer	60	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 204	proteomic profiling by mass spectrometer	60	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 204	proteomic profiling by mass spectrometer	60	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 204	proteomic profiling by mass spectrometer	60	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 204	proteomic profiling by mass spectrometer	60	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 204	proteomic profiling by mass spectrometer	60	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 204	proteomic profiling by mass spectrometer	60	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 205	proteomic profiling by mass spectrometer	61	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 205	proteomic profiling by mass spectrometer	61	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 205	proteomic profiling by mass spectrometer	61	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 205	proteomic profiling by mass spectrometer	61	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 205	proteomic profiling by mass spectrometer	61	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 205	proteomic profiling by mass spectrometer	61	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 205	proteomic profiling by mass spectrometer	61	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 205	proteomic profiling by mass spectrometer	61	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 205	proteomic profiling by mass spectrometer	61	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 205	proteomic profiling by mass spectrometer	61	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 206	proteomic profiling by mass spectrometer	62	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 206	proteomic profiling by mass spectrometer	62	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 206	proteomic profiling by mass spectrometer	62	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 206	proteomic profiling by mass spectrometer	62	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 206	proteomic profiling by mass spectrometer	62	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 206	proteomic profiling by mass spectrometer	62	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 206	proteomic profiling by mass spectrometer	62	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 206	proteomic profiling by mass spectrometer	62	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 206	proteomic profiling by mass spectrometer	62	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 206	proteomic profiling by mass spectrometer	62	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 207	proteomic profiling by mass spectrometer	63	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 207	proteomic profiling by mass spectrometer	63	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 207	proteomic profiling by mass spectrometer	63	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 207	proteomic profiling by mass spectrometer	63	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 207	proteomic profiling by mass spectrometer	63	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 207	proteomic profiling by mass spectrometer	63	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 207	proteomic profiling by mass spectrometer	63	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 207	proteomic profiling by mass spectrometer	63	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 207	proteomic profiling by mass spectrometer	63	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 207	proteomic profiling by mass spectrometer	63	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 208	proteomic profiling by mass spectrometer	64	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 208	proteomic profiling by mass spectrometer	64	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 208	proteomic profiling by mass spectrometer	64	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 208	proteomic profiling by mass spectrometer	64	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 208	proteomic profiling by mass spectrometer	64	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 208	proteomic profiling by mass spectrometer	64	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 208	proteomic profiling by mass spectrometer	64	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 208	proteomic profiling by mass spectrometer	64	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 208	proteomic profiling by mass spectrometer	64	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 208	proteomic profiling by mass spectrometer	64	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 209	proteomic profiling by mass spectrometer	65	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 209	proteomic profiling by mass spectrometer	65	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 209	proteomic profiling by mass spectrometer	65	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 209	proteomic profiling by mass spectrometer	65	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 209	proteomic profiling by mass spectrometer	65	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 209	proteomic profiling by mass spectrometer	65	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 209	proteomic profiling by mass spectrometer	65	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 209	proteomic profiling by mass spectrometer	65	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 209	proteomic profiling by mass spectrometer	65	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 209	proteomic profiling by mass spectrometer	65	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 210	proteomic profiling by mass spectrometer	66	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 210	proteomic profiling by mass spectrometer	66	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 210	proteomic profiling by mass spectrometer	66	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 210	proteomic profiling by mass spectrometer	66	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 210	proteomic profiling by mass spectrometer	66	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 210	proteomic profiling by mass spectrometer	66	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 210	proteomic profiling by mass spectrometer	66	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 210	proteomic profiling by mass spectrometer	66	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 210	proteomic profiling by mass spectrometer	66	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 210	proteomic profiling by mass spectrometer	66	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 211	proteomic profiling by mass spectrometer	67	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 211	proteomic profiling by mass spectrometer	67	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 211	proteomic profiling by mass spectrometer	67	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 211	proteomic profiling by mass spectrometer	67	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 211	proteomic profiling by mass spectrometer	67	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 211	proteomic profiling by mass spectrometer	67	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 211	proteomic profiling by mass spectrometer	67	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 211	proteomic profiling by mass spectrometer	67	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 211	proteomic profiling by mass spectrometer	67	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 211	proteomic profiling by mass spectrometer	67	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 212	proteomic profiling by mass spectrometer	68	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 212	proteomic profiling by mass spectrometer	68	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 212	proteomic profiling by mass spectrometer	68	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 212	proteomic profiling by mass spectrometer	68	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 212	proteomic profiling by mass spectrometer	68	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 212	proteomic profiling by mass spectrometer	68	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 212	proteomic profiling by mass spectrometer	68	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 212	proteomic profiling by mass spectrometer	68	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 212	proteomic profiling by mass spectrometer	68	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 212	proteomic profiling by mass spectrometer	68	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 213	proteomic profiling by mass spectrometer	69	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 213	proteomic profiling by mass spectrometer	69	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 213	proteomic profiling by mass spectrometer	69	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 213	proteomic profiling by mass spectrometer	69	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 213	proteomic profiling by mass spectrometer	69	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 213	proteomic profiling by mass spectrometer	69	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 213	proteomic profiling by mass spectrometer	69	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 213	proteomic profiling by mass spectrometer	69	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 213	proteomic profiling by mass spectrometer	69	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 213	proteomic profiling by mass spectrometer	69	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 214	proteomic profiling by mass spectrometer	70	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 214	proteomic profiling by mass spectrometer	70	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 214	proteomic profiling by mass spectrometer	70	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 214	proteomic profiling by mass spectrometer	70	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 214	proteomic profiling by mass spectrometer	70	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 214	proteomic profiling by mass spectrometer	70	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 214	proteomic profiling by mass spectrometer	70	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 214	proteomic profiling by mass spectrometer	70	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 214	proteomic profiling by mass spectrometer	70	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 214	proteomic profiling by mass spectrometer	70	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 215	proteomic profiling by mass spectrometer	71	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 215	proteomic profiling by mass spectrometer	71	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 215	proteomic profiling by mass spectrometer	71	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 215	proteomic profiling by mass spectrometer	71	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 215	proteomic profiling by mass spectrometer	71	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 215	proteomic profiling by mass spectrometer	71	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 215	proteomic profiling by mass spectrometer	71	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 215	proteomic profiling by mass spectrometer	71	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 215	proteomic profiling by mass spectrometer	71	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 215	proteomic profiling by mass spectrometer	71	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	run 216	proteomic profiling by mass spectrometer	72	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	run 216	proteomic profiling by mass spectrometer	72	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	run 216	proteomic profiling by mass spectrometer	72	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	run 216	proteomic profiling by mass spectrometer	72	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	run 216	proteomic profiling by mass spectrometer	72	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	run 216	proteomic profiling by mass spectrometer	72	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	run 216	proteomic profiling by mass spectrometer	72	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	run 216	proteomic profiling by mass spectrometer	72	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	run 216	proteomic profiling by mass spectrometer	72	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	run 216	proteomic profiling by mass spectrometer	72	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 217	proteomic profiling by mass spectrometer	1	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 217	proteomic profiling by mass spectrometer	1	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 217	proteomic profiling by mass spectrometer	1	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 217	proteomic profiling by mass spectrometer	1	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 217	proteomic profiling by mass spectrometer	1	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 217	proteomic profiling by mass spectrometer	1	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 217	proteomic profiling by mass spectrometer	1	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 217	proteomic profiling by mass spectrometer	1	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 217	proteomic profiling by mass spectrometer	1	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 217	proteomic profiling by mass spectrometer	1	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 218	proteomic profiling by mass spectrometer	2	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 218	proteomic profiling by mass spectrometer	2	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 218	proteomic profiling by mass spectrometer	2	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 218	proteomic profiling by mass spectrometer	2	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 218	proteomic profiling by mass spectrometer	2	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 218	proteomic profiling by mass spectrometer	2	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 218	proteomic profiling by mass spectrometer	2	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 218	proteomic profiling by mass spectrometer	2	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 218	proteomic profiling by mass spectrometer	2	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 218	proteomic profiling by mass spectrometer	2	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 219	proteomic profiling by mass spectrometer	3	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 219	proteomic profiling by mass spectrometer	3	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 219	proteomic profiling by mass spectrometer	3	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 219	proteomic profiling by mass spectrometer	3	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 219	proteomic profiling by mass spectrometer	3	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 219	proteomic profiling by mass spectrometer	3	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 219	proteomic profiling by mass spectrometer	3	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 219	proteomic profiling by mass spectrometer	3	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 219	proteomic profiling by mass spectrometer	3	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 219	proteomic profiling by mass spectrometer	3	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 220	proteomic profiling by mass spectrometer	4	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 220	proteomic profiling by mass spectrometer	4	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 220	proteomic profiling by mass spectrometer	4	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 220	proteomic profiling by mass spectrometer	4	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 220	proteomic profiling by mass spectrometer	4	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 220	proteomic profiling by mass spectrometer	4	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 220	proteomic profiling by mass spectrometer	4	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 220	proteomic profiling by mass spectrometer	4	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 220	proteomic profiling by mass spectrometer	4	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 220	proteomic profiling by mass spectrometer	4	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 221	proteomic profiling by mass spectrometer	5	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 221	proteomic profiling by mass spectrometer	5	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 221	proteomic profiling by mass spectrometer	5	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 221	proteomic profiling by mass spectrometer	5	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 221	proteomic profiling by mass spectrometer	5	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 221	proteomic profiling by mass spectrometer	5	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 221	proteomic profiling by mass spectrometer	5	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 221	proteomic profiling by mass spectrometer	5	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 221	proteomic profiling by mass spectrometer	5	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 221	proteomic profiling by mass spectrometer	5	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 222	proteomic profiling by mass spectrometer	6	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 222	proteomic profiling by mass spectrometer	6	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 222	proteomic profiling by mass spectrometer	6	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 222	proteomic profiling by mass spectrometer	6	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 222	proteomic profiling by mass spectrometer	6	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 222	proteomic profiling by mass spectrometer	6	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 222	proteomic profiling by mass spectrometer	6	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 222	proteomic profiling by mass spectrometer	6	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 222	proteomic profiling by mass spectrometer	6	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 222	proteomic profiling by mass spectrometer	6	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 223	proteomic profiling by mass spectrometer	7	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 223	proteomic profiling by mass spectrometer	7	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 223	proteomic profiling by mass spectrometer	7	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 223	proteomic profiling by mass spectrometer	7	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 223	proteomic profiling by mass spectrometer	7	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 223	proteomic profiling by mass spectrometer	7	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 223	proteomic profiling by mass spectrometer	7	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 223	proteomic profiling by mass spectrometer	7	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 223	proteomic profiling by mass spectrometer	7	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 223	proteomic profiling by mass spectrometer	7	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 224	proteomic profiling by mass spectrometer	8	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 224	proteomic profiling by mass spectrometer	8	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 224	proteomic profiling by mass spectrometer	8	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 224	proteomic profiling by mass spectrometer	8	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 224	proteomic profiling by mass spectrometer	8	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 224	proteomic profiling by mass spectrometer	8	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 224	proteomic profiling by mass spectrometer	8	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 224	proteomic profiling by mass spectrometer	8	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 224	proteomic profiling by mass spectrometer	8	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 224	proteomic profiling by mass spectrometer	8	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 225	proteomic profiling by mass spectrometer	9	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 225	proteomic profiling by mass spectrometer	9	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 225	proteomic profiling by mass spectrometer	9	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 225	proteomic profiling by mass spectrometer	9	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 225	proteomic profiling by mass spectrometer	9	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 225	proteomic profiling by mass spectrometer	9	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 225	proteomic profiling by mass spectrometer	9	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 225	proteomic profiling by mass spectrometer	9	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 225	proteomic profiling by mass spectrometer	9	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 225	proteomic profiling by mass spectrometer	9	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 226	proteomic profiling by mass spectrometer	10	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 226	proteomic profiling by mass spectrometer	10	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 226	proteomic profiling by mass spectrometer	10	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 226	proteomic profiling by mass spectrometer	10	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 226	proteomic profiling by mass spectrometer	10	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 226	proteomic profiling by mass spectrometer	10	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 226	proteomic profiling by mass spectrometer	10	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 226	proteomic profiling by mass spectrometer	10	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 226	proteomic profiling by mass spectrometer	10	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 226	proteomic profiling by mass spectrometer	10	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 227	proteomic profiling by mass spectrometer	11	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 227	proteomic profiling by mass spectrometer	11	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 227	proteomic profiling by mass spectrometer	11	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 227	proteomic profiling by mass spectrometer	11	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 227	proteomic profiling by mass spectrometer	11	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 227	proteomic profiling by mass spectrometer	11	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 227	proteomic profiling by mass spectrometer	11	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 227	proteomic profiling by mass spectrometer	11	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 227	proteomic profiling by mass spectrometer	11	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 227	proteomic profiling by mass spectrometer	11	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 228	proteomic profiling by mass spectrometer	12	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 228	proteomic profiling by mass spectrometer	12	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 228	proteomic profiling by mass spectrometer	12	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 228	proteomic profiling by mass spectrometer	12	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 228	proteomic profiling by mass spectrometer	12	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 228	proteomic profiling by mass spectrometer	12	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 228	proteomic profiling by mass spectrometer	12	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 228	proteomic profiling by mass spectrometer	12	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 228	proteomic profiling by mass spectrometer	12	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 228	proteomic profiling by mass spectrometer	12	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 229	proteomic profiling by mass spectrometer	13	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 229	proteomic profiling by mass spectrometer	13	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 229	proteomic profiling by mass spectrometer	13	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 229	proteomic profiling by mass spectrometer	13	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 229	proteomic profiling by mass spectrometer	13	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 229	proteomic profiling by mass spectrometer	13	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 229	proteomic profiling by mass spectrometer	13	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 229	proteomic profiling by mass spectrometer	13	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 229	proteomic profiling by mass spectrometer	13	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 229	proteomic profiling by mass spectrometer	13	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 230	proteomic profiling by mass spectrometer	14	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 230	proteomic profiling by mass spectrometer	14	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 230	proteomic profiling by mass spectrometer	14	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 230	proteomic profiling by mass spectrometer	14	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 230	proteomic profiling by mass spectrometer	14	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 230	proteomic profiling by mass spectrometer	14	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 230	proteomic profiling by mass spectrometer	14	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 230	proteomic profiling by mass spectrometer	14	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 230	proteomic profiling by mass spectrometer	14	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 230	proteomic profiling by mass spectrometer	14	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 231	proteomic profiling by mass spectrometer	15	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 231	proteomic profiling by mass spectrometer	15	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 231	proteomic profiling by mass spectrometer	15	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 231	proteomic profiling by mass spectrometer	15	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 231	proteomic profiling by mass spectrometer	15	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 231	proteomic profiling by mass spectrometer	15	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 231	proteomic profiling by mass spectrometer	15	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 231	proteomic profiling by mass spectrometer	15	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 231	proteomic profiling by mass spectrometer	15	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 231	proteomic profiling by mass spectrometer	15	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 232	proteomic profiling by mass spectrometer	16	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 232	proteomic profiling by mass spectrometer	16	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 232	proteomic profiling by mass spectrometer	16	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 232	proteomic profiling by mass spectrometer	16	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 232	proteomic profiling by mass spectrometer	16	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 232	proteomic profiling by mass spectrometer	16	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 232	proteomic profiling by mass spectrometer	16	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 232	proteomic profiling by mass spectrometer	16	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 232	proteomic profiling by mass spectrometer	16	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 232	proteomic profiling by mass spectrometer	16	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 233	proteomic profiling by mass spectrometer	17	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 233	proteomic profiling by mass spectrometer	17	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 233	proteomic profiling by mass spectrometer	17	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 233	proteomic profiling by mass spectrometer	17	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 233	proteomic profiling by mass spectrometer	17	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 233	proteomic profiling by mass spectrometer	17	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 233	proteomic profiling by mass spectrometer	17	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 233	proteomic profiling by mass spectrometer	17	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 233	proteomic profiling by mass spectrometer	17	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 233	proteomic profiling by mass spectrometer	17	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 234	proteomic profiling by mass spectrometer	18	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 234	proteomic profiling by mass spectrometer	18	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 234	proteomic profiling by mass spectrometer	18	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 234	proteomic profiling by mass spectrometer	18	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 234	proteomic profiling by mass spectrometer	18	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 234	proteomic profiling by mass spectrometer	18	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 234	proteomic profiling by mass spectrometer	18	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 234	proteomic profiling by mass spectrometer	18	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 234	proteomic profiling by mass spectrometer	18	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 234	proteomic profiling by mass spectrometer	18	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 235	proteomic profiling by mass spectrometer	19	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 235	proteomic profiling by mass spectrometer	19	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 235	proteomic profiling by mass spectrometer	19	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 235	proteomic profiling by mass spectrometer	19	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 235	proteomic profiling by mass spectrometer	19	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 235	proteomic profiling by mass spectrometer	19	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 235	proteomic profiling by mass spectrometer	19	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 235	proteomic profiling by mass spectrometer	19	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 235	proteomic profiling by mass spectrometer	19	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 235	proteomic profiling by mass spectrometer	19	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 236	proteomic profiling by mass spectrometer	20	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 236	proteomic profiling by mass spectrometer	20	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 236	proteomic profiling by mass spectrometer	20	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 236	proteomic profiling by mass spectrometer	20	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 236	proteomic profiling by mass spectrometer	20	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 236	proteomic profiling by mass spectrometer	20	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 236	proteomic profiling by mass spectrometer	20	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 236	proteomic profiling by mass spectrometer	20	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 236	proteomic profiling by mass spectrometer	20	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 236	proteomic profiling by mass spectrometer	20	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 237	proteomic profiling by mass spectrometer	21	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 237	proteomic profiling by mass spectrometer	21	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 237	proteomic profiling by mass spectrometer	21	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 237	proteomic profiling by mass spectrometer	21	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 237	proteomic profiling by mass spectrometer	21	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 237	proteomic profiling by mass spectrometer	21	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 237	proteomic profiling by mass spectrometer	21	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 237	proteomic profiling by mass spectrometer	21	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 237	proteomic profiling by mass spectrometer	21	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 237	proteomic profiling by mass spectrometer	21	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 238	proteomic profiling by mass spectrometer	22	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 238	proteomic profiling by mass spectrometer	22	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 238	proteomic profiling by mass spectrometer	22	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 238	proteomic profiling by mass spectrometer	22	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 238	proteomic profiling by mass spectrometer	22	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 238	proteomic profiling by mass spectrometer	22	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 238	proteomic profiling by mass spectrometer	22	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 238	proteomic profiling by mass spectrometer	22	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 238	proteomic profiling by mass spectrometer	22	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 238	proteomic profiling by mass spectrometer	22	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 239	proteomic profiling by mass spectrometer	23	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 239	proteomic profiling by mass spectrometer	23	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 239	proteomic profiling by mass spectrometer	23	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 239	proteomic profiling by mass spectrometer	23	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 239	proteomic profiling by mass spectrometer	23	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 239	proteomic profiling by mass spectrometer	23	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 239	proteomic profiling by mass spectrometer	23	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 239	proteomic profiling by mass spectrometer	23	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 239	proteomic profiling by mass spectrometer	23	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 239	proteomic profiling by mass spectrometer	23	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 240	proteomic profiling by mass spectrometer	24	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 240	proteomic profiling by mass spectrometer	24	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 240	proteomic profiling by mass spectrometer	24	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 240	proteomic profiling by mass spectrometer	24	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 240	proteomic profiling by mass spectrometer	24	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 240	proteomic profiling by mass spectrometer	24	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 240	proteomic profiling by mass spectrometer	24	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 240	proteomic profiling by mass spectrometer	24	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 240	proteomic profiling by mass spectrometer	24	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 240	proteomic profiling by mass spectrometer	24	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 241	proteomic profiling by mass spectrometer	25	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 241	proteomic profiling by mass spectrometer	25	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 241	proteomic profiling by mass spectrometer	25	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 241	proteomic profiling by mass spectrometer	25	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 241	proteomic profiling by mass spectrometer	25	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 241	proteomic profiling by mass spectrometer	25	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 241	proteomic profiling by mass spectrometer	25	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 241	proteomic profiling by mass spectrometer	25	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 241	proteomic profiling by mass spectrometer	25	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 241	proteomic profiling by mass spectrometer	25	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 242	proteomic profiling by mass spectrometer	26	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 242	proteomic profiling by mass spectrometer	26	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 242	proteomic profiling by mass spectrometer	26	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 242	proteomic profiling by mass spectrometer	26	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 242	proteomic profiling by mass spectrometer	26	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 242	proteomic profiling by mass spectrometer	26	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 242	proteomic profiling by mass spectrometer	26	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 242	proteomic profiling by mass spectrometer	26	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 242	proteomic profiling by mass spectrometer	26	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 242	proteomic profiling by mass spectrometer	26	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 243	proteomic profiling by mass spectrometer	27	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 243	proteomic profiling by mass spectrometer	27	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 243	proteomic profiling by mass spectrometer	27	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 243	proteomic profiling by mass spectrometer	27	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 243	proteomic profiling by mass spectrometer	27	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 243	proteomic profiling by mass spectrometer	27	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 243	proteomic profiling by mass spectrometer	27	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 243	proteomic profiling by mass spectrometer	27	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 243	proteomic profiling by mass spectrometer	27	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 243	proteomic profiling by mass spectrometer	27	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 244	proteomic profiling by mass spectrometer	28	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 244	proteomic profiling by mass spectrometer	28	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 244	proteomic profiling by mass spectrometer	28	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 244	proteomic profiling by mass spectrometer	28	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 244	proteomic profiling by mass spectrometer	28	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 244	proteomic profiling by mass spectrometer	28	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 244	proteomic profiling by mass spectrometer	28	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 244	proteomic profiling by mass spectrometer	28	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 244	proteomic profiling by mass spectrometer	28	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 244	proteomic profiling by mass spectrometer	28	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 245	proteomic profiling by mass spectrometer	29	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 245	proteomic profiling by mass spectrometer	29	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 245	proteomic profiling by mass spectrometer	29	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 245	proteomic profiling by mass spectrometer	29	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 245	proteomic profiling by mass spectrometer	29	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 245	proteomic profiling by mass spectrometer	29	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 245	proteomic profiling by mass spectrometer	29	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 245	proteomic profiling by mass spectrometer	29	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 245	proteomic profiling by mass spectrometer	29	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 245	proteomic profiling by mass spectrometer	29	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 246	proteomic profiling by mass spectrometer	30	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 246	proteomic profiling by mass spectrometer	30	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 246	proteomic profiling by mass spectrometer	30	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 246	proteomic profiling by mass spectrometer	30	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 246	proteomic profiling by mass spectrometer	30	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 246	proteomic profiling by mass spectrometer	30	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 246	proteomic profiling by mass spectrometer	30	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 246	proteomic profiling by mass spectrometer	30	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 246	proteomic profiling by mass spectrometer	30	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 246	proteomic profiling by mass spectrometer	30	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 247	proteomic profiling by mass spectrometer	31	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 247	proteomic profiling by mass spectrometer	31	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 247	proteomic profiling by mass spectrometer	31	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 247	proteomic profiling by mass spectrometer	31	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 247	proteomic profiling by mass spectrometer	31	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 247	proteomic profiling by mass spectrometer	31	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 247	proteomic profiling by mass spectrometer	31	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 247	proteomic profiling by mass spectrometer	31	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 247	proteomic profiling by mass spectrometer	31	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 247	proteomic profiling by mass spectrometer	31	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 248	proteomic profiling by mass spectrometer	32	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 248	proteomic profiling by mass spectrometer	32	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 248	proteomic profiling by mass spectrometer	32	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 248	proteomic profiling by mass spectrometer	32	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 248	proteomic profiling by mass spectrometer	32	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 248	proteomic profiling by mass spectrometer	32	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 248	proteomic profiling by mass spectrometer	32	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 248	proteomic profiling by mass spectrometer	32	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 248	proteomic profiling by mass spectrometer	32	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 248	proteomic profiling by mass spectrometer	32	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 249	proteomic profiling by mass spectrometer	33	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 249	proteomic profiling by mass spectrometer	33	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 249	proteomic profiling by mass spectrometer	33	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 249	proteomic profiling by mass spectrometer	33	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 249	proteomic profiling by mass spectrometer	33	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 249	proteomic profiling by mass spectrometer	33	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 249	proteomic profiling by mass spectrometer	33	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 249	proteomic profiling by mass spectrometer	33	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 249	proteomic profiling by mass spectrometer	33	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 249	proteomic profiling by mass spectrometer	33	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 250	proteomic profiling by mass spectrometer	34	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 250	proteomic profiling by mass spectrometer	34	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 250	proteomic profiling by mass spectrometer	34	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 250	proteomic profiling by mass spectrometer	34	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 250	proteomic profiling by mass spectrometer	34	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 250	proteomic profiling by mass spectrometer	34	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 250	proteomic profiling by mass spectrometer	34	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 250	proteomic profiling by mass spectrometer	34	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 250	proteomic profiling by mass spectrometer	34	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 250	proteomic profiling by mass spectrometer	34	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 251	proteomic profiling by mass spectrometer	35	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 251	proteomic profiling by mass spectrometer	35	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 251	proteomic profiling by mass spectrometer	35	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 251	proteomic profiling by mass spectrometer	35	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 251	proteomic profiling by mass spectrometer	35	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 251	proteomic profiling by mass spectrometer	35	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 251	proteomic profiling by mass spectrometer	35	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 251	proteomic profiling by mass spectrometer	35	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 251	proteomic profiling by mass spectrometer	35	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 251	proteomic profiling by mass spectrometer	35	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 252	proteomic profiling by mass spectrometer	36	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 252	proteomic profiling by mass spectrometer	36	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 252	proteomic profiling by mass spectrometer	36	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 252	proteomic profiling by mass spectrometer	36	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 252	proteomic profiling by mass spectrometer	36	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 252	proteomic profiling by mass spectrometer	36	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 252	proteomic profiling by mass spectrometer	36	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 252	proteomic profiling by mass spectrometer	36	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 252	proteomic profiling by mass spectrometer	36	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 252	proteomic profiling by mass spectrometer	36	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 253	proteomic profiling by mass spectrometer	37	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 253	proteomic profiling by mass spectrometer	37	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 253	proteomic profiling by mass spectrometer	37	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 253	proteomic profiling by mass spectrometer	37	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 253	proteomic profiling by mass spectrometer	37	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 253	proteomic profiling by mass spectrometer	37	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 253	proteomic profiling by mass spectrometer	37	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 253	proteomic profiling by mass spectrometer	37	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 253	proteomic profiling by mass spectrometer	37	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 253	proteomic profiling by mass spectrometer	37	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 254	proteomic profiling by mass spectrometer	38	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 254	proteomic profiling by mass spectrometer	38	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 254	proteomic profiling by mass spectrometer	38	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 254	proteomic profiling by mass spectrometer	38	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 254	proteomic profiling by mass spectrometer	38	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 254	proteomic profiling by mass spectrometer	38	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 254	proteomic profiling by mass spectrometer	38	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 254	proteomic profiling by mass spectrometer	38	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 254	proteomic profiling by mass spectrometer	38	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 254	proteomic profiling by mass spectrometer	38	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 255	proteomic profiling by mass spectrometer	39	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 255	proteomic profiling by mass spectrometer	39	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 255	proteomic profiling by mass spectrometer	39	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 255	proteomic profiling by mass spectrometer	39	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 255	proteomic profiling by mass spectrometer	39	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 255	proteomic profiling by mass spectrometer	39	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 255	proteomic profiling by mass spectrometer	39	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 255	proteomic profiling by mass spectrometer	39	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 255	proteomic profiling by mass spectrometer	39	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 255	proteomic profiling by mass spectrometer	39	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 256	proteomic profiling by mass spectrometer	40	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 256	proteomic profiling by mass spectrometer	40	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 256	proteomic profiling by mass spectrometer	40	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 256	proteomic profiling by mass spectrometer	40	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 256	proteomic profiling by mass spectrometer	40	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 256	proteomic profiling by mass spectrometer	40	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 256	proteomic profiling by mass spectrometer	40	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 256	proteomic profiling by mass spectrometer	40	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 256	proteomic profiling by mass spectrometer	40	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 256	proteomic profiling by mass spectrometer	40	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 257	proteomic profiling by mass spectrometer	41	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 257	proteomic profiling by mass spectrometer	41	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 257	proteomic profiling by mass spectrometer	41	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 257	proteomic profiling by mass spectrometer	41	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 257	proteomic profiling by mass spectrometer	41	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 257	proteomic profiling by mass spectrometer	41	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 257	proteomic profiling by mass spectrometer	41	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 257	proteomic profiling by mass spectrometer	41	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 257	proteomic profiling by mass spectrometer	41	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 257	proteomic profiling by mass spectrometer	41	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 258	proteomic profiling by mass spectrometer	42	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 258	proteomic profiling by mass spectrometer	42	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 258	proteomic profiling by mass spectrometer	42	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 258	proteomic profiling by mass spectrometer	42	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 258	proteomic profiling by mass spectrometer	42	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 258	proteomic profiling by mass spectrometer	42	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 258	proteomic profiling by mass spectrometer	42	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 258	proteomic profiling by mass spectrometer	42	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 258	proteomic profiling by mass spectrometer	42	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 258	proteomic profiling by mass spectrometer	42	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 259	proteomic profiling by mass spectrometer	43	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 259	proteomic profiling by mass spectrometer	43	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 259	proteomic profiling by mass spectrometer	43	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 259	proteomic profiling by mass spectrometer	43	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 259	proteomic profiling by mass spectrometer	43	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 259	proteomic profiling by mass spectrometer	43	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 259	proteomic profiling by mass spectrometer	43	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 259	proteomic profiling by mass spectrometer	43	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 259	proteomic profiling by mass spectrometer	43	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 259	proteomic profiling by mass spectrometer	43	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 260	proteomic profiling by mass spectrometer	44	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 260	proteomic profiling by mass spectrometer	44	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 260	proteomic profiling by mass spectrometer	44	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 260	proteomic profiling by mass spectrometer	44	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 260	proteomic profiling by mass spectrometer	44	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 260	proteomic profiling by mass spectrometer	44	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 260	proteomic profiling by mass spectrometer	44	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 260	proteomic profiling by mass spectrometer	44	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 260	proteomic profiling by mass spectrometer	44	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 260	proteomic profiling by mass spectrometer	44	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 261	proteomic profiling by mass spectrometer	45	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 261	proteomic profiling by mass spectrometer	45	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 261	proteomic profiling by mass spectrometer	45	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 261	proteomic profiling by mass spectrometer	45	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 261	proteomic profiling by mass spectrometer	45	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 261	proteomic profiling by mass spectrometer	45	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 261	proteomic profiling by mass spectrometer	45	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 261	proteomic profiling by mass spectrometer	45	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 261	proteomic profiling by mass spectrometer	45	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 261	proteomic profiling by mass spectrometer	45	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 262	proteomic profiling by mass spectrometer	46	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 262	proteomic profiling by mass spectrometer	46	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 262	proteomic profiling by mass spectrometer	46	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 262	proteomic profiling by mass spectrometer	46	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 262	proteomic profiling by mass spectrometer	46	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 262	proteomic profiling by mass spectrometer	46	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 262	proteomic profiling by mass spectrometer	46	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 262	proteomic profiling by mass spectrometer	46	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 262	proteomic profiling by mass spectrometer	46	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 262	proteomic profiling by mass spectrometer	46	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 263	proteomic profiling by mass spectrometer	47	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 263	proteomic profiling by mass spectrometer	47	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 263	proteomic profiling by mass spectrometer	47	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 263	proteomic profiling by mass spectrometer	47	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 263	proteomic profiling by mass spectrometer	47	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 263	proteomic profiling by mass spectrometer	47	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 263	proteomic profiling by mass spectrometer	47	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 263	proteomic profiling by mass spectrometer	47	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 263	proteomic profiling by mass spectrometer	47	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 263	proteomic profiling by mass spectrometer	47	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 264	proteomic profiling by mass spectrometer	48	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 264	proteomic profiling by mass spectrometer	48	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 264	proteomic profiling by mass spectrometer	48	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 264	proteomic profiling by mass spectrometer	48	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 264	proteomic profiling by mass spectrometer	48	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 264	proteomic profiling by mass spectrometer	48	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 264	proteomic profiling by mass spectrometer	48	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 264	proteomic profiling by mass spectrometer	48	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 264	proteomic profiling by mass spectrometer	48	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 264	proteomic profiling by mass spectrometer	48	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 265	proteomic profiling by mass spectrometer	49	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 265	proteomic profiling by mass spectrometer	49	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 265	proteomic profiling by mass spectrometer	49	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 265	proteomic profiling by mass spectrometer	49	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 265	proteomic profiling by mass spectrometer	49	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 265	proteomic profiling by mass spectrometer	49	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 265	proteomic profiling by mass spectrometer	49	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 265	proteomic profiling by mass spectrometer	49	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 265	proteomic profiling by mass spectrometer	49	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 265	proteomic profiling by mass spectrometer	49	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 266	proteomic profiling by mass spectrometer	50	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 266	proteomic profiling by mass spectrometer	50	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 266	proteomic profiling by mass spectrometer	50	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 266	proteomic profiling by mass spectrometer	50	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 266	proteomic profiling by mass spectrometer	50	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 266	proteomic profiling by mass spectrometer	50	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 266	proteomic profiling by mass spectrometer	50	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 266	proteomic profiling by mass spectrometer	50	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 266	proteomic profiling by mass spectrometer	50	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 266	proteomic profiling by mass spectrometer	50	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 267	proteomic profiling by mass spectrometer	51	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 267	proteomic profiling by mass spectrometer	51	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 267	proteomic profiling by mass spectrometer	51	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 267	proteomic profiling by mass spectrometer	51	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 267	proteomic profiling by mass spectrometer	51	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 267	proteomic profiling by mass spectrometer	51	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 267	proteomic profiling by mass spectrometer	51	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 267	proteomic profiling by mass spectrometer	51	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 267	proteomic profiling by mass spectrometer	51	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 267	proteomic profiling by mass spectrometer	51	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 268	proteomic profiling by mass spectrometer	52	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 268	proteomic profiling by mass spectrometer	52	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 268	proteomic profiling by mass spectrometer	52	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 268	proteomic profiling by mass spectrometer	52	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 268	proteomic profiling by mass spectrometer	52	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 268	proteomic profiling by mass spectrometer	52	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 268	proteomic profiling by mass spectrometer	52	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 268	proteomic profiling by mass spectrometer	52	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 268	proteomic profiling by mass spectrometer	52	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 268	proteomic profiling by mass spectrometer	52	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 269	proteomic profiling by mass spectrometer	53	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 269	proteomic profiling by mass spectrometer	53	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 269	proteomic profiling by mass spectrometer	53	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 269	proteomic profiling by mass spectrometer	53	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 269	proteomic profiling by mass spectrometer	53	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 269	proteomic profiling by mass spectrometer	53	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 269	proteomic profiling by mass spectrometer	53	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 269	proteomic profiling by mass spectrometer	53	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 269	proteomic profiling by mass spectrometer	53	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 269	proteomic profiling by mass spectrometer	53	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 270	proteomic profiling by mass spectrometer	54	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 270	proteomic profiling by mass spectrometer	54	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 270	proteomic profiling by mass spectrometer	54	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 270	proteomic profiling by mass spectrometer	54	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 270	proteomic profiling by mass spectrometer	54	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 270	proteomic profiling by mass spectrometer	54	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 270	proteomic profiling by mass spectrometer	54	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 270	proteomic profiling by mass spectrometer	54	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 270	proteomic profiling by mass spectrometer	54	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 270	proteomic profiling by mass spectrometer	54	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 271	proteomic profiling by mass spectrometer	55	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 271	proteomic profiling by mass spectrometer	55	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 271	proteomic profiling by mass spectrometer	55	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 271	proteomic profiling by mass spectrometer	55	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 271	proteomic profiling by mass spectrometer	55	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 271	proteomic profiling by mass spectrometer	55	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 271	proteomic profiling by mass spectrometer	55	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 271	proteomic profiling by mass spectrometer	55	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 271	proteomic profiling by mass spectrometer	55	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 271	proteomic profiling by mass spectrometer	55	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 272	proteomic profiling by mass spectrometer	56	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 272	proteomic profiling by mass spectrometer	56	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 272	proteomic profiling by mass spectrometer	56	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 272	proteomic profiling by mass spectrometer	56	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 272	proteomic profiling by mass spectrometer	56	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 272	proteomic profiling by mass spectrometer	56	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 272	proteomic profiling by mass spectrometer	56	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 272	proteomic profiling by mass spectrometer	56	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 272	proteomic profiling by mass spectrometer	56	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 272	proteomic profiling by mass spectrometer	56	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 273	proteomic profiling by mass spectrometer	57	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 273	proteomic profiling by mass spectrometer	57	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 273	proteomic profiling by mass spectrometer	57	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 273	proteomic profiling by mass spectrometer	57	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 273	proteomic profiling by mass spectrometer	57	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 273	proteomic profiling by mass spectrometer	57	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 273	proteomic profiling by mass spectrometer	57	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 273	proteomic profiling by mass spectrometer	57	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 273	proteomic profiling by mass spectrometer	57	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 273	proteomic profiling by mass spectrometer	57	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 274	proteomic profiling by mass spectrometer	58	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 274	proteomic profiling by mass spectrometer	58	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 274	proteomic profiling by mass spectrometer	58	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 274	proteomic profiling by mass spectrometer	58	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 274	proteomic profiling by mass spectrometer	58	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 274	proteomic profiling by mass spectrometer	58	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 274	proteomic profiling by mass spectrometer	58	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 274	proteomic profiling by mass spectrometer	58	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 274	proteomic profiling by mass spectrometer	58	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 274	proteomic profiling by mass spectrometer	58	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 275	proteomic profiling by mass spectrometer	59	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 275	proteomic profiling by mass spectrometer	59	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 275	proteomic profiling by mass spectrometer	59	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 275	proteomic profiling by mass spectrometer	59	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 275	proteomic profiling by mass spectrometer	59	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 275	proteomic profiling by mass spectrometer	59	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 275	proteomic profiling by mass spectrometer	59	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 275	proteomic profiling by mass spectrometer	59	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 275	proteomic profiling by mass spectrometer	59	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 275	proteomic profiling by mass spectrometer	59	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 276	proteomic profiling by mass spectrometer	60	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 276	proteomic profiling by mass spectrometer	60	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 276	proteomic profiling by mass spectrometer	60	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 276	proteomic profiling by mass spectrometer	60	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 276	proteomic profiling by mass spectrometer	60	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 276	proteomic profiling by mass spectrometer	60	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 276	proteomic profiling by mass spectrometer	60	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 276	proteomic profiling by mass spectrometer	60	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 276	proteomic profiling by mass spectrometer	60	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 276	proteomic profiling by mass spectrometer	60	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 277	proteomic profiling by mass spectrometer	61	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 277	proteomic profiling by mass spectrometer	61	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 277	proteomic profiling by mass spectrometer	61	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 277	proteomic profiling by mass spectrometer	61	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 277	proteomic profiling by mass spectrometer	61	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 277	proteomic profiling by mass spectrometer	61	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 277	proteomic profiling by mass spectrometer	61	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 277	proteomic profiling by mass spectrometer	61	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 277	proteomic profiling by mass spectrometer	61	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 277	proteomic profiling by mass spectrometer	61	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 278	proteomic profiling by mass spectrometer	62	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 278	proteomic profiling by mass spectrometer	62	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 278	proteomic profiling by mass spectrometer	62	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 278	proteomic profiling by mass spectrometer	62	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 278	proteomic profiling by mass spectrometer	62	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 278	proteomic profiling by mass spectrometer	62	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 278	proteomic profiling by mass spectrometer	62	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 278	proteomic profiling by mass spectrometer	62	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 278	proteomic profiling by mass spectrometer	62	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 278	proteomic profiling by mass spectrometer	62	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 279	proteomic profiling by mass spectrometer	63	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 279	proteomic profiling by mass spectrometer	63	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 279	proteomic profiling by mass spectrometer	63	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 279	proteomic profiling by mass spectrometer	63	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 279	proteomic profiling by mass spectrometer	63	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 279	proteomic profiling by mass spectrometer	63	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 279	proteomic profiling by mass spectrometer	63	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 279	proteomic profiling by mass spectrometer	63	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 279	proteomic profiling by mass spectrometer	63	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 279	proteomic profiling by mass spectrometer	63	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 280	proteomic profiling by mass spectrometer	64	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 280	proteomic profiling by mass spectrometer	64	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 280	proteomic profiling by mass spectrometer	64	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 280	proteomic profiling by mass spectrometer	64	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 280	proteomic profiling by mass spectrometer	64	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 280	proteomic profiling by mass spectrometer	64	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 280	proteomic profiling by mass spectrometer	64	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 280	proteomic profiling by mass spectrometer	64	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 280	proteomic profiling by mass spectrometer	64	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 280	proteomic profiling by mass spectrometer	64	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 281	proteomic profiling by mass spectrometer	65	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 281	proteomic profiling by mass spectrometer	65	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 281	proteomic profiling by mass spectrometer	65	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 281	proteomic profiling by mass spectrometer	65	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 281	proteomic profiling by mass spectrometer	65	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 281	proteomic profiling by mass spectrometer	65	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 281	proteomic profiling by mass spectrometer	65	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 281	proteomic profiling by mass spectrometer	65	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 281	proteomic profiling by mass spectrometer	65	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 281	proteomic profiling by mass spectrometer	65	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 282	proteomic profiling by mass spectrometer	66	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 282	proteomic profiling by mass spectrometer	66	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 282	proteomic profiling by mass spectrometer	66	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 282	proteomic profiling by mass spectrometer	66	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 282	proteomic profiling by mass spectrometer	66	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 282	proteomic profiling by mass spectrometer	66	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 282	proteomic profiling by mass spectrometer	66	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 282	proteomic profiling by mass spectrometer	66	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 282	proteomic profiling by mass spectrometer	66	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 282	proteomic profiling by mass spectrometer	66	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 283	proteomic profiling by mass spectrometer	67	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 283	proteomic profiling by mass spectrometer	67	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 283	proteomic profiling by mass spectrometer	67	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 283	proteomic profiling by mass spectrometer	67	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 283	proteomic profiling by mass spectrometer	67	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 283	proteomic profiling by mass spectrometer	67	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 283	proteomic profiling by mass spectrometer	67	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 283	proteomic profiling by mass spectrometer	67	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 283	proteomic profiling by mass spectrometer	67	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 283	proteomic profiling by mass spectrometer	67	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 284	proteomic profiling by mass spectrometer	68	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 284	proteomic profiling by mass spectrometer	68	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 284	proteomic profiling by mass spectrometer	68	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 284	proteomic profiling by mass spectrometer	68	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 284	proteomic profiling by mass spectrometer	68	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 284	proteomic profiling by mass spectrometer	68	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 284	proteomic profiling by mass spectrometer	68	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 284	proteomic profiling by mass spectrometer	68	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 284	proteomic profiling by mass spectrometer	68	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 284	proteomic profiling by mass spectrometer	68	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 285	proteomic profiling by mass spectrometer	69	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 285	proteomic profiling by mass spectrometer	69	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 285	proteomic profiling by mass spectrometer	69	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 285	proteomic profiling by mass spectrometer	69	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 285	proteomic profiling by mass spectrometer	69	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 285	proteomic profiling by mass spectrometer	69	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 285	proteomic profiling by mass spectrometer	69	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 285	proteomic profiling by mass spectrometer	69	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 285	proteomic profiling by mass spectrometer	69	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 285	proteomic profiling by mass spectrometer	69	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 286	proteomic profiling by mass spectrometer	70	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 286	proteomic profiling by mass spectrometer	70	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 286	proteomic profiling by mass spectrometer	70	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 286	proteomic profiling by mass spectrometer	70	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 286	proteomic profiling by mass spectrometer	70	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 286	proteomic profiling by mass spectrometer	70	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 286	proteomic profiling by mass spectrometer	70	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 286	proteomic profiling by mass spectrometer	70	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 286	proteomic profiling by mass spectrometer	70	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 286	proteomic profiling by mass spectrometer	70	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 287	proteomic profiling by mass spectrometer	71	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 287	proteomic profiling by mass spectrometer	71	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 287	proteomic profiling by mass spectrometer	71	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 287	proteomic profiling by mass spectrometer	71	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 287	proteomic profiling by mass spectrometer	71	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 287	proteomic profiling by mass spectrometer	71	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 287	proteomic profiling by mass spectrometer	71	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 287	proteomic profiling by mass spectrometer	71	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 287	proteomic profiling by mass spectrometer	71	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 287	proteomic profiling by mass spectrometer	71	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	run 288	proteomic profiling by mass spectrometer	72	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	run 288	proteomic profiling by mass spectrometer	72	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	run 288	proteomic profiling by mass spectrometer	72	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	run 288	proteomic profiling by mass spectrometer	72	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	run 288	proteomic profiling by mass spectrometer	72	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	run 288	proteomic profiling by mass spectrometer	72	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	run 288	proteomic profiling by mass spectrometer	72	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	run 288	proteomic profiling by mass spectrometer	72	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	run 288	proteomic profiling by mass spectrometer	72	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	run 288	proteomic profiling by mass spectrometer	72	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 289	proteomic profiling by mass spectrometer	1	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 289	proteomic profiling by mass spectrometer	1	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 289	proteomic profiling by mass spectrometer	1	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 289	proteomic profiling by mass spectrometer	1	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 289	proteomic profiling by mass spectrometer	1	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 289	proteomic profiling by mass spectrometer	1	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 289	proteomic profiling by mass spectrometer	1	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 289	proteomic profiling by mass spectrometer	1	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 289	proteomic profiling by mass spectrometer	1	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 289	proteomic profiling by mass spectrometer	1	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 290	proteomic profiling by mass spectrometer	2	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 290	proteomic profiling by mass spectrometer	2	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 290	proteomic profiling by mass spectrometer	2	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 290	proteomic profiling by mass spectrometer	2	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 290	proteomic profiling by mass spectrometer	2	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 290	proteomic profiling by mass spectrometer	2	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 290	proteomic profiling by mass spectrometer	2	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 290	proteomic profiling by mass spectrometer	2	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 290	proteomic profiling by mass spectrometer	2	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 290	proteomic profiling by mass spectrometer	2	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 291	proteomic profiling by mass spectrometer	3	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 291	proteomic profiling by mass spectrometer	3	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 291	proteomic profiling by mass spectrometer	3	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 291	proteomic profiling by mass spectrometer	3	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 291	proteomic profiling by mass spectrometer	3	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 291	proteomic profiling by mass spectrometer	3	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 291	proteomic profiling by mass spectrometer	3	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 291	proteomic profiling by mass spectrometer	3	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 291	proteomic profiling by mass spectrometer	3	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 291	proteomic profiling by mass spectrometer	3	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 292	proteomic profiling by mass spectrometer	4	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 292	proteomic profiling by mass spectrometer	4	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 292	proteomic profiling by mass spectrometer	4	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 292	proteomic profiling by mass spectrometer	4	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 292	proteomic profiling by mass spectrometer	4	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 292	proteomic profiling by mass spectrometer	4	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 292	proteomic profiling by mass spectrometer	4	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 292	proteomic profiling by mass spectrometer	4	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 292	proteomic profiling by mass spectrometer	4	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 292	proteomic profiling by mass spectrometer	4	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 293	proteomic profiling by mass spectrometer	5	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 293	proteomic profiling by mass spectrometer	5	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 293	proteomic profiling by mass spectrometer	5	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 293	proteomic profiling by mass spectrometer	5	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 293	proteomic profiling by mass spectrometer	5	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 293	proteomic profiling by mass spectrometer	5	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 293	proteomic profiling by mass spectrometer	5	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 293	proteomic profiling by mass spectrometer	5	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 293	proteomic profiling by mass spectrometer	5	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 293	proteomic profiling by mass spectrometer	5	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 294	proteomic profiling by mass spectrometer	6	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 294	proteomic profiling by mass spectrometer	6	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 294	proteomic profiling by mass spectrometer	6	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 294	proteomic profiling by mass spectrometer	6	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 294	proteomic profiling by mass spectrometer	6	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 294	proteomic profiling by mass spectrometer	6	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 294	proteomic profiling by mass spectrometer	6	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 294	proteomic profiling by mass spectrometer	6	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 294	proteomic profiling by mass spectrometer	6	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 294	proteomic profiling by mass spectrometer	6	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 295	proteomic profiling by mass spectrometer	7	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 295	proteomic profiling by mass spectrometer	7	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 295	proteomic profiling by mass spectrometer	7	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 295	proteomic profiling by mass spectrometer	7	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 295	proteomic profiling by mass spectrometer	7	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 295	proteomic profiling by mass spectrometer	7	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 295	proteomic profiling by mass spectrometer	7	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 295	proteomic profiling by mass spectrometer	7	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 295	proteomic profiling by mass spectrometer	7	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 295	proteomic profiling by mass spectrometer	7	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 296	proteomic profiling by mass spectrometer	8	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 296	proteomic profiling by mass spectrometer	8	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 296	proteomic profiling by mass spectrometer	8	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 296	proteomic profiling by mass spectrometer	8	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 296	proteomic profiling by mass spectrometer	8	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 296	proteomic profiling by mass spectrometer	8	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 296	proteomic profiling by mass spectrometer	8	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 296	proteomic profiling by mass spectrometer	8	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 296	proteomic profiling by mass spectrometer	8	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 296	proteomic profiling by mass spectrometer	8	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 297	proteomic profiling by mass spectrometer	9	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 297	proteomic profiling by mass spectrometer	9	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 297	proteomic profiling by mass spectrometer	9	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 297	proteomic profiling by mass spectrometer	9	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 297	proteomic profiling by mass spectrometer	9	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 297	proteomic profiling by mass spectrometer	9	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 297	proteomic profiling by mass spectrometer	9	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 297	proteomic profiling by mass spectrometer	9	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 297	proteomic profiling by mass spectrometer	9	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 297	proteomic profiling by mass spectrometer	9	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 298	proteomic profiling by mass spectrometer	10	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 298	proteomic profiling by mass spectrometer	10	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 298	proteomic profiling by mass spectrometer	10	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 298	proteomic profiling by mass spectrometer	10	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 298	proteomic profiling by mass spectrometer	10	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 298	proteomic profiling by mass spectrometer	10	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 298	proteomic profiling by mass spectrometer	10	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 298	proteomic profiling by mass spectrometer	10	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 298	proteomic profiling by mass spectrometer	10	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 298	proteomic profiling by mass spectrometer	10	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 299	proteomic profiling by mass spectrometer	11	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 299	proteomic profiling by mass spectrometer	11	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 299	proteomic profiling by mass spectrometer	11	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 299	proteomic profiling by mass spectrometer	11	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 299	proteomic profiling by mass spectrometer	11	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 299	proteomic profiling by mass spectrometer	11	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 299	proteomic profiling by mass spectrometer	11	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 299	proteomic profiling by mass spectrometer	11	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 299	proteomic profiling by mass spectrometer	11	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 299	proteomic profiling by mass spectrometer	11	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 300	proteomic profiling by mass spectrometer	12	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 300	proteomic profiling by mass spectrometer	12	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 300	proteomic profiling by mass spectrometer	12	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 300	proteomic profiling by mass spectrometer	12	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 300	proteomic profiling by mass spectrometer	12	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 300	proteomic profiling by mass spectrometer	12	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 300	proteomic profiling by mass spectrometer	12	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 300	proteomic profiling by mass spectrometer	12	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 300	proteomic profiling by mass spectrometer	12	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 300	proteomic profiling by mass spectrometer	12	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 301	proteomic profiling by mass spectrometer	13	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 301	proteomic profiling by mass spectrometer	13	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 301	proteomic profiling by mass spectrometer	13	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 301	proteomic profiling by mass spectrometer	13	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 301	proteomic profiling by mass spectrometer	13	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 301	proteomic profiling by mass spectrometer	13	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 301	proteomic profiling by mass spectrometer	13	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 301	proteomic profiling by mass spectrometer	13	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 301	proteomic profiling by mass spectrometer	13	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 301	proteomic profiling by mass spectrometer	13	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 302	proteomic profiling by mass spectrometer	14	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 302	proteomic profiling by mass spectrometer	14	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 302	proteomic profiling by mass spectrometer	14	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 302	proteomic profiling by mass spectrometer	14	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 302	proteomic profiling by mass spectrometer	14	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 302	proteomic profiling by mass spectrometer	14	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 302	proteomic profiling by mass spectrometer	14	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 302	proteomic profiling by mass spectrometer	14	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 302	proteomic profiling by mass spectrometer	14	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 302	proteomic profiling by mass spectrometer	14	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 303	proteomic profiling by mass spectrometer	15	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 303	proteomic profiling by mass spectrometer	15	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 303	proteomic profiling by mass spectrometer	15	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 303	proteomic profiling by mass spectrometer	15	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 303	proteomic profiling by mass spectrometer	15	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 303	proteomic profiling by mass spectrometer	15	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 303	proteomic profiling by mass spectrometer	15	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 303	proteomic profiling by mass spectrometer	15	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 303	proteomic profiling by mass spectrometer	15	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 303	proteomic profiling by mass spectrometer	15	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 304	proteomic profiling by mass spectrometer	16	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 304	proteomic profiling by mass spectrometer	16	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 304	proteomic profiling by mass spectrometer	16	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 304	proteomic profiling by mass spectrometer	16	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 304	proteomic profiling by mass spectrometer	16	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 304	proteomic profiling by mass spectrometer	16	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 304	proteomic profiling by mass spectrometer	16	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 304	proteomic profiling by mass spectrometer	16	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 304	proteomic profiling by mass spectrometer	16	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 304	proteomic profiling by mass spectrometer	16	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 305	proteomic profiling by mass spectrometer	17	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 305	proteomic profiling by mass spectrometer	17	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 305	proteomic profiling by mass spectrometer	17	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 305	proteomic profiling by mass spectrometer	17	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 305	proteomic profiling by mass spectrometer	17	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 305	proteomic profiling by mass spectrometer	17	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 305	proteomic profiling by mass spectrometer	17	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 305	proteomic profiling by mass spectrometer	17	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 305	proteomic profiling by mass spectrometer	17	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 305	proteomic profiling by mass spectrometer	17	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 306	proteomic profiling by mass spectrometer	18	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 306	proteomic profiling by mass spectrometer	18	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 306	proteomic profiling by mass spectrometer	18	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 306	proteomic profiling by mass spectrometer	18	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 306	proteomic profiling by mass spectrometer	18	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 306	proteomic profiling by mass spectrometer	18	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 306	proteomic profiling by mass spectrometer	18	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 306	proteomic profiling by mass spectrometer	18	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 306	proteomic profiling by mass spectrometer	18	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 306	proteomic profiling by mass spectrometer	18	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 307	proteomic profiling by mass spectrometer	19	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 307	proteomic profiling by mass spectrometer	19	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 307	proteomic profiling by mass spectrometer	19	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 307	proteomic profiling by mass spectrometer	19	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 307	proteomic profiling by mass spectrometer	19	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 307	proteomic profiling by mass spectrometer	19	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 307	proteomic profiling by mass spectrometer	19	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 307	proteomic profiling by mass spectrometer	19	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 307	proteomic profiling by mass spectrometer	19	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 307	proteomic profiling by mass spectrometer	19	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 308	proteomic profiling by mass spectrometer	20	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 308	proteomic profiling by mass spectrometer	20	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 308	proteomic profiling by mass spectrometer	20	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 308	proteomic profiling by mass spectrometer	20	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 308	proteomic profiling by mass spectrometer	20	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 308	proteomic profiling by mass spectrometer	20	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 308	proteomic profiling by mass spectrometer	20	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 308	proteomic profiling by mass spectrometer	20	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 308	proteomic profiling by mass spectrometer	20	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 308	proteomic profiling by mass spectrometer	20	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 309	proteomic profiling by mass spectrometer	21	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 309	proteomic profiling by mass spectrometer	21	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 309	proteomic profiling by mass spectrometer	21	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 309	proteomic profiling by mass spectrometer	21	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 309	proteomic profiling by mass spectrometer	21	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 309	proteomic profiling by mass spectrometer	21	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 309	proteomic profiling by mass spectrometer	21	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 309	proteomic profiling by mass spectrometer	21	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 309	proteomic profiling by mass spectrometer	21	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 309	proteomic profiling by mass spectrometer	21	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 310	proteomic profiling by mass spectrometer	22	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 310	proteomic profiling by mass spectrometer	22	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 310	proteomic profiling by mass spectrometer	22	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 310	proteomic profiling by mass spectrometer	22	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 310	proteomic profiling by mass spectrometer	22	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 310	proteomic profiling by mass spectrometer	22	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 310	proteomic profiling by mass spectrometer	22	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 310	proteomic profiling by mass spectrometer	22	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 310	proteomic profiling by mass spectrometer	22	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 310	proteomic profiling by mass spectrometer	22	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 311	proteomic profiling by mass spectrometer	23	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 311	proteomic profiling by mass spectrometer	23	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 311	proteomic profiling by mass spectrometer	23	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 311	proteomic profiling by mass spectrometer	23	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 311	proteomic profiling by mass spectrometer	23	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 311	proteomic profiling by mass spectrometer	23	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 311	proteomic profiling by mass spectrometer	23	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 311	proteomic profiling by mass spectrometer	23	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 311	proteomic profiling by mass spectrometer	23	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 311	proteomic profiling by mass spectrometer	23	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 312	proteomic profiling by mass spectrometer	24	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 312	proteomic profiling by mass spectrometer	24	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 312	proteomic profiling by mass spectrometer	24	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 312	proteomic profiling by mass spectrometer	24	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 312	proteomic profiling by mass spectrometer	24	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 312	proteomic profiling by mass spectrometer	24	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 312	proteomic profiling by mass spectrometer	24	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 312	proteomic profiling by mass spectrometer	24	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 312	proteomic profiling by mass spectrometer	24	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 312	proteomic profiling by mass spectrometer	24	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 313	proteomic profiling by mass spectrometer	25	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 313	proteomic profiling by mass spectrometer	25	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 313	proteomic profiling by mass spectrometer	25	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 313	proteomic profiling by mass spectrometer	25	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 313	proteomic profiling by mass spectrometer	25	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 313	proteomic profiling by mass spectrometer	25	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 313	proteomic profiling by mass spectrometer	25	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 313	proteomic profiling by mass spectrometer	25	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 313	proteomic profiling by mass spectrometer	25	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 313	proteomic profiling by mass spectrometer	25	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 314	proteomic profiling by mass spectrometer	26	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 314	proteomic profiling by mass spectrometer	26	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 314	proteomic profiling by mass spectrometer	26	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 314	proteomic profiling by mass spectrometer	26	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 314	proteomic profiling by mass spectrometer	26	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 314	proteomic profiling by mass spectrometer	26	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 314	proteomic profiling by mass spectrometer	26	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 314	proteomic profiling by mass spectrometer	26	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 314	proteomic profiling by mass spectrometer	26	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 314	proteomic profiling by mass spectrometer	26	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 315	proteomic profiling by mass spectrometer	27	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 315	proteomic profiling by mass spectrometer	27	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 315	proteomic profiling by mass spectrometer	27	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 315	proteomic profiling by mass spectrometer	27	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 315	proteomic profiling by mass spectrometer	27	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 315	proteomic profiling by mass spectrometer	27	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 315	proteomic profiling by mass spectrometer	27	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 315	proteomic profiling by mass spectrometer	27	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 315	proteomic profiling by mass spectrometer	27	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 315	proteomic profiling by mass spectrometer	27	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 316	proteomic profiling by mass spectrometer	28	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 316	proteomic profiling by mass spectrometer	28	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 316	proteomic profiling by mass spectrometer	28	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 316	proteomic profiling by mass spectrometer	28	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 316	proteomic profiling by mass spectrometer	28	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 316	proteomic profiling by mass spectrometer	28	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 316	proteomic profiling by mass spectrometer	28	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 316	proteomic profiling by mass spectrometer	28	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 316	proteomic profiling by mass spectrometer	28	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 316	proteomic profiling by mass spectrometer	28	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 317	proteomic profiling by mass spectrometer	29	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 317	proteomic profiling by mass spectrometer	29	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 317	proteomic profiling by mass spectrometer	29	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 317	proteomic profiling by mass spectrometer	29	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 317	proteomic profiling by mass spectrometer	29	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 317	proteomic profiling by mass spectrometer	29	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 317	proteomic profiling by mass spectrometer	29	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 317	proteomic profiling by mass spectrometer	29	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 317	proteomic profiling by mass spectrometer	29	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 317	proteomic profiling by mass spectrometer	29	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 318	proteomic profiling by mass spectrometer	30	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 318	proteomic profiling by mass spectrometer	30	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 318	proteomic profiling by mass spectrometer	30	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 318	proteomic profiling by mass spectrometer	30	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 318	proteomic profiling by mass spectrometer	30	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 318	proteomic profiling by mass spectrometer	30	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 318	proteomic profiling by mass spectrometer	30	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 318	proteomic profiling by mass spectrometer	30	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 318	proteomic profiling by mass spectrometer	30	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 318	proteomic profiling by mass spectrometer	30	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 319	proteomic profiling by mass spectrometer	31	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 319	proteomic profiling by mass spectrometer	31	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 319	proteomic profiling by mass spectrometer	31	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 319	proteomic profiling by mass spectrometer	31	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 319	proteomic profiling by mass spectrometer	31	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 319	proteomic profiling by mass spectrometer	31	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 319	proteomic profiling by mass spectrometer	31	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 319	proteomic profiling by mass spectrometer	31	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 319	proteomic profiling by mass spectrometer	31	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 319	proteomic profiling by mass spectrometer	31	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 320	proteomic profiling by mass spectrometer	32	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 320	proteomic profiling by mass spectrometer	32	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 320	proteomic profiling by mass spectrometer	32	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 320	proteomic profiling by mass spectrometer	32	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 320	proteomic profiling by mass spectrometer	32	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 320	proteomic profiling by mass spectrometer	32	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 320	proteomic profiling by mass spectrometer	32	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 320	proteomic profiling by mass spectrometer	32	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 320	proteomic profiling by mass spectrometer	32	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 320	proteomic profiling by mass spectrometer	32	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 321	proteomic profiling by mass spectrometer	33	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 321	proteomic profiling by mass spectrometer	33	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 321	proteomic profiling by mass spectrometer	33	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 321	proteomic profiling by mass spectrometer	33	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 321	proteomic profiling by mass spectrometer	33	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 321	proteomic profiling by mass spectrometer	33	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 321	proteomic profiling by mass spectrometer	33	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 321	proteomic profiling by mass spectrometer	33	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 321	proteomic profiling by mass spectrometer	33	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 321	proteomic profiling by mass spectrometer	33	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 322	proteomic profiling by mass spectrometer	34	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 322	proteomic profiling by mass spectrometer	34	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 322	proteomic profiling by mass spectrometer	34	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 322	proteomic profiling by mass spectrometer	34	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 322	proteomic profiling by mass spectrometer	34	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 322	proteomic profiling by mass spectrometer	34	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 322	proteomic profiling by mass spectrometer	34	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 322	proteomic profiling by mass spectrometer	34	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 322	proteomic profiling by mass spectrometer	34	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 322	proteomic profiling by mass spectrometer	34	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 323	proteomic profiling by mass spectrometer	35	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 323	proteomic profiling by mass spectrometer	35	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 323	proteomic profiling by mass spectrometer	35	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 323	proteomic profiling by mass spectrometer	35	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 323	proteomic profiling by mass spectrometer	35	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 323	proteomic profiling by mass spectrometer	35	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 323	proteomic profiling by mass spectrometer	35	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 323	proteomic profiling by mass spectrometer	35	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 323	proteomic profiling by mass spectrometer	35	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 323	proteomic profiling by mass spectrometer	35	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 324	proteomic profiling by mass spectrometer	36	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 324	proteomic profiling by mass spectrometer	36	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 324	proteomic profiling by mass spectrometer	36	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 324	proteomic profiling by mass spectrometer	36	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 324	proteomic profiling by mass spectrometer	36	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 324	proteomic profiling by mass spectrometer	36	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 324	proteomic profiling by mass spectrometer	36	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 324	proteomic profiling by mass spectrometer	36	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 324	proteomic profiling by mass spectrometer	36	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 324	proteomic profiling by mass spectrometer	36	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 325	proteomic profiling by mass spectrometer	37	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 325	proteomic profiling by mass spectrometer	37	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 325	proteomic profiling by mass spectrometer	37	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 325	proteomic profiling by mass spectrometer	37	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 325	proteomic profiling by mass spectrometer	37	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 325	proteomic profiling by mass spectrometer	37	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 325	proteomic profiling by mass spectrometer	37	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 325	proteomic profiling by mass spectrometer	37	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 325	proteomic profiling by mass spectrometer	37	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 325	proteomic profiling by mass spectrometer	37	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 326	proteomic profiling by mass spectrometer	38	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 326	proteomic profiling by mass spectrometer	38	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 326	proteomic profiling by mass spectrometer	38	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 326	proteomic profiling by mass spectrometer	38	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 326	proteomic profiling by mass spectrometer	38	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 326	proteomic profiling by mass spectrometer	38	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 326	proteomic profiling by mass spectrometer	38	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 326	proteomic profiling by mass spectrometer	38	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 326	proteomic profiling by mass spectrometer	38	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 326	proteomic profiling by mass spectrometer	38	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 327	proteomic profiling by mass spectrometer	39	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 327	proteomic profiling by mass spectrometer	39	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 327	proteomic profiling by mass spectrometer	39	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 327	proteomic profiling by mass spectrometer	39	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 327	proteomic profiling by mass spectrometer	39	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 327	proteomic profiling by mass spectrometer	39	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 327	proteomic profiling by mass spectrometer	39	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 327	proteomic profiling by mass spectrometer	39	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 327	proteomic profiling by mass spectrometer	39	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 327	proteomic profiling by mass spectrometer	39	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 328	proteomic profiling by mass spectrometer	40	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 328	proteomic profiling by mass spectrometer	40	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 328	proteomic profiling by mass spectrometer	40	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 328	proteomic profiling by mass spectrometer	40	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 328	proteomic profiling by mass spectrometer	40	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 328	proteomic profiling by mass spectrometer	40	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 328	proteomic profiling by mass spectrometer	40	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 328	proteomic profiling by mass spectrometer	40	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 328	proteomic profiling by mass spectrometer	40	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 328	proteomic profiling by mass spectrometer	40	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 329	proteomic profiling by mass spectrometer	41	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 329	proteomic profiling by mass spectrometer	41	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 329	proteomic profiling by mass spectrometer	41	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 329	proteomic profiling by mass spectrometer	41	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 329	proteomic profiling by mass spectrometer	41	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 329	proteomic profiling by mass spectrometer	41	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 329	proteomic profiling by mass spectrometer	41	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 329	proteomic profiling by mass spectrometer	41	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 329	proteomic profiling by mass spectrometer	41	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 329	proteomic profiling by mass spectrometer	41	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 330	proteomic profiling by mass spectrometer	42	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 330	proteomic profiling by mass spectrometer	42	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 330	proteomic profiling by mass spectrometer	42	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 330	proteomic profiling by mass spectrometer	42	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 330	proteomic profiling by mass spectrometer	42	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 330	proteomic profiling by mass spectrometer	42	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 330	proteomic profiling by mass spectrometer	42	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 330	proteomic profiling by mass spectrometer	42	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 330	proteomic profiling by mass spectrometer	42	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 330	proteomic profiling by mass spectrometer	42	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 331	proteomic profiling by mass spectrometer	43	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 331	proteomic profiling by mass spectrometer	43	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 331	proteomic profiling by mass spectrometer	43	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 331	proteomic profiling by mass spectrometer	43	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 331	proteomic profiling by mass spectrometer	43	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 331	proteomic profiling by mass spectrometer	43	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 331	proteomic profiling by mass spectrometer	43	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 331	proteomic profiling by mass spectrometer	43	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 331	proteomic profiling by mass spectrometer	43	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 331	proteomic profiling by mass spectrometer	43	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 332	proteomic profiling by mass spectrometer	44	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 332	proteomic profiling by mass spectrometer	44	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 332	proteomic profiling by mass spectrometer	44	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 332	proteomic profiling by mass spectrometer	44	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 332	proteomic profiling by mass spectrometer	44	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 332	proteomic profiling by mass spectrometer	44	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 332	proteomic profiling by mass spectrometer	44	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 332	proteomic profiling by mass spectrometer	44	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 332	proteomic profiling by mass spectrometer	44	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 332	proteomic profiling by mass spectrometer	44	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 333	proteomic profiling by mass spectrometer	45	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 333	proteomic profiling by mass spectrometer	45	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 333	proteomic profiling by mass spectrometer	45	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 333	proteomic profiling by mass spectrometer	45	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 333	proteomic profiling by mass spectrometer	45	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 333	proteomic profiling by mass spectrometer	45	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 333	proteomic profiling by mass spectrometer	45	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 333	proteomic profiling by mass spectrometer	45	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 333	proteomic profiling by mass spectrometer	45	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 333	proteomic profiling by mass spectrometer	45	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 334	proteomic profiling by mass spectrometer	46	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 334	proteomic profiling by mass spectrometer	46	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 334	proteomic profiling by mass spectrometer	46	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 334	proteomic profiling by mass spectrometer	46	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 334	proteomic profiling by mass spectrometer	46	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 334	proteomic profiling by mass spectrometer	46	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 334	proteomic profiling by mass spectrometer	46	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 334	proteomic profiling by mass spectrometer	46	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 334	proteomic profiling by mass spectrometer	46	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 334	proteomic profiling by mass spectrometer	46	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 335	proteomic profiling by mass spectrometer	47	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 335	proteomic profiling by mass spectrometer	47	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 335	proteomic profiling by mass spectrometer	47	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 335	proteomic profiling by mass spectrometer	47	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 335	proteomic profiling by mass spectrometer	47	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 335	proteomic profiling by mass spectrometer	47	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 335	proteomic profiling by mass spectrometer	47	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 335	proteomic profiling by mass spectrometer	47	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 335	proteomic profiling by mass spectrometer	47	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 335	proteomic profiling by mass spectrometer	47	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 336	proteomic profiling by mass spectrometer	48	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 336	proteomic profiling by mass spectrometer	48	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 336	proteomic profiling by mass spectrometer	48	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 336	proteomic profiling by mass spectrometer	48	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 336	proteomic profiling by mass spectrometer	48	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 336	proteomic profiling by mass spectrometer	48	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 336	proteomic profiling by mass spectrometer	48	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 336	proteomic profiling by mass spectrometer	48	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 336	proteomic profiling by mass spectrometer	48	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 336	proteomic profiling by mass spectrometer	48	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 337	proteomic profiling by mass spectrometer	49	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 337	proteomic profiling by mass spectrometer	49	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 337	proteomic profiling by mass spectrometer	49	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 337	proteomic profiling by mass spectrometer	49	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 337	proteomic profiling by mass spectrometer	49	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 337	proteomic profiling by mass spectrometer	49	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 337	proteomic profiling by mass spectrometer	49	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 337	proteomic profiling by mass spectrometer	49	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 337	proteomic profiling by mass spectrometer	49	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 337	proteomic profiling by mass spectrometer	49	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 338	proteomic profiling by mass spectrometer	50	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 338	proteomic profiling by mass spectrometer	50	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 338	proteomic profiling by mass spectrometer	50	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 338	proteomic profiling by mass spectrometer	50	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 338	proteomic profiling by mass spectrometer	50	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 338	proteomic profiling by mass spectrometer	50	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 338	proteomic profiling by mass spectrometer	50	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 338	proteomic profiling by mass spectrometer	50	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 338	proteomic profiling by mass spectrometer	50	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 338	proteomic profiling by mass spectrometer	50	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 339	proteomic profiling by mass spectrometer	51	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 339	proteomic profiling by mass spectrometer	51	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 339	proteomic profiling by mass spectrometer	51	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 339	proteomic profiling by mass spectrometer	51	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 339	proteomic profiling by mass spectrometer	51	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 339	proteomic profiling by mass spectrometer	51	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 339	proteomic profiling by mass spectrometer	51	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 339	proteomic profiling by mass spectrometer	51	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 339	proteomic profiling by mass spectrometer	51	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 339	proteomic profiling by mass spectrometer	51	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 340	proteomic profiling by mass spectrometer	52	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 340	proteomic profiling by mass spectrometer	52	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 340	proteomic profiling by mass spectrometer	52	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 340	proteomic profiling by mass spectrometer	52	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 340	proteomic profiling by mass spectrometer	52	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 340	proteomic profiling by mass spectrometer	52	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 340	proteomic profiling by mass spectrometer	52	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 340	proteomic profiling by mass spectrometer	52	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 340	proteomic profiling by mass spectrometer	52	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 340	proteomic profiling by mass spectrometer	52	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 341	proteomic profiling by mass spectrometer	53	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 341	proteomic profiling by mass spectrometer	53	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 341	proteomic profiling by mass spectrometer	53	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 341	proteomic profiling by mass spectrometer	53	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 341	proteomic profiling by mass spectrometer	53	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 341	proteomic profiling by mass spectrometer	53	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 341	proteomic profiling by mass spectrometer	53	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 341	proteomic profiling by mass spectrometer	53	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 341	proteomic profiling by mass spectrometer	53	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 341	proteomic profiling by mass spectrometer	53	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 342	proteomic profiling by mass spectrometer	54	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 342	proteomic profiling by mass spectrometer	54	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 342	proteomic profiling by mass spectrometer	54	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 342	proteomic profiling by mass spectrometer	54	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 342	proteomic profiling by mass spectrometer	54	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 342	proteomic profiling by mass spectrometer	54	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 342	proteomic profiling by mass spectrometer	54	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 342	proteomic profiling by mass spectrometer	54	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 342	proteomic profiling by mass spectrometer	54	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 342	proteomic profiling by mass spectrometer	54	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 343	proteomic profiling by mass spectrometer	55	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 343	proteomic profiling by mass spectrometer	55	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 343	proteomic profiling by mass spectrometer	55	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 343	proteomic profiling by mass spectrometer	55	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 343	proteomic profiling by mass spectrometer	55	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 343	proteomic profiling by mass spectrometer	55	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 343	proteomic profiling by mass spectrometer	55	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 343	proteomic profiling by mass spectrometer	55	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 343	proteomic profiling by mass spectrometer	55	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 343	proteomic profiling by mass spectrometer	55	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 344	proteomic profiling by mass spectrometer	56	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 344	proteomic profiling by mass spectrometer	56	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 344	proteomic profiling by mass spectrometer	56	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 344	proteomic profiling by mass spectrometer	56	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 344	proteomic profiling by mass spectrometer	56	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 344	proteomic profiling by mass spectrometer	56	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 344	proteomic profiling by mass spectrometer	56	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 344	proteomic profiling by mass spectrometer	56	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 344	proteomic profiling by mass spectrometer	56	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 344	proteomic profiling by mass spectrometer	56	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 345	proteomic profiling by mass spectrometer	57	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 345	proteomic profiling by mass spectrometer	57	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 345	proteomic profiling by mass spectrometer	57	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 345	proteomic profiling by mass spectrometer	57	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 345	proteomic profiling by mass spectrometer	57	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 345	proteomic profiling by mass spectrometer	57	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 345	proteomic profiling by mass spectrometer	57	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 345	proteomic profiling by mass spectrometer	57	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 345	proteomic profiling by mass spectrometer	57	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 345	proteomic profiling by mass spectrometer	57	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 346	proteomic profiling by mass spectrometer	58	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 346	proteomic profiling by mass spectrometer	58	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 346	proteomic profiling by mass spectrometer	58	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 346	proteomic profiling by mass spectrometer	58	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 346	proteomic profiling by mass spectrometer	58	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 346	proteomic profiling by mass spectrometer	58	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 346	proteomic profiling by mass spectrometer	58	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 346	proteomic profiling by mass spectrometer	58	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 346	proteomic profiling by mass spectrometer	58	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 346	proteomic profiling by mass spectrometer	58	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 347	proteomic profiling by mass spectrometer	59	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 347	proteomic profiling by mass spectrometer	59	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 347	proteomic profiling by mass spectrometer	59	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 347	proteomic profiling by mass spectrometer	59	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 347	proteomic profiling by mass spectrometer	59	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 347	proteomic profiling by mass spectrometer	59	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 347	proteomic profiling by mass spectrometer	59	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 347	proteomic profiling by mass spectrometer	59	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 347	proteomic profiling by mass spectrometer	59	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 347	proteomic profiling by mass spectrometer	59	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 348	proteomic profiling by mass spectrometer	60	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 348	proteomic profiling by mass spectrometer	60	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 348	proteomic profiling by mass spectrometer	60	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 348	proteomic profiling by mass spectrometer	60	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 348	proteomic profiling by mass spectrometer	60	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 348	proteomic profiling by mass spectrometer	60	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 348	proteomic profiling by mass spectrometer	60	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 348	proteomic profiling by mass spectrometer	60	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 348	proteomic profiling by mass spectrometer	60	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 348	proteomic profiling by mass spectrometer	60	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 349	proteomic profiling by mass spectrometer	61	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 349	proteomic profiling by mass spectrometer	61	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 349	proteomic profiling by mass spectrometer	61	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 349	proteomic profiling by mass spectrometer	61	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 349	proteomic profiling by mass spectrometer	61	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 349	proteomic profiling by mass spectrometer	61	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 349	proteomic profiling by mass spectrometer	61	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 349	proteomic profiling by mass spectrometer	61	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 349	proteomic profiling by mass spectrometer	61	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 349	proteomic profiling by mass spectrometer	61	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 350	proteomic profiling by mass spectrometer	62	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 350	proteomic profiling by mass spectrometer	62	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 350	proteomic profiling by mass spectrometer	62	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 350	proteomic profiling by mass spectrometer	62	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 350	proteomic profiling by mass spectrometer	62	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 350	proteomic profiling by mass spectrometer	62	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 350	proteomic profiling by mass spectrometer	62	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 350	proteomic profiling by mass spectrometer	62	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 350	proteomic profiling by mass spectrometer	62	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 350	proteomic profiling by mass spectrometer	62	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 351	proteomic profiling by mass spectrometer	63	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 351	proteomic profiling by mass spectrometer	63	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 351	proteomic profiling by mass spectrometer	63	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 351	proteomic profiling by mass spectrometer	63	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 351	proteomic profiling by mass spectrometer	63	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 351	proteomic profiling by mass spectrometer	63	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 351	proteomic profiling by mass spectrometer	63	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 351	proteomic profiling by mass spectrometer	63	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 351	proteomic profiling by mass spectrometer	63	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 351	proteomic profiling by mass spectrometer	63	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 352	proteomic profiling by mass spectrometer	64	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 352	proteomic profiling by mass spectrometer	64	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 352	proteomic profiling by mass spectrometer	64	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 352	proteomic profiling by mass spectrometer	64	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 352	proteomic profiling by mass spectrometer	64	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 352	proteomic profiling by mass spectrometer	64	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 352	proteomic profiling by mass spectrometer	64	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 352	proteomic profiling by mass spectrometer	64	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 352	proteomic profiling by mass spectrometer	64	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 352	proteomic profiling by mass spectrometer	64	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 353	proteomic profiling by mass spectrometer	65	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 353	proteomic profiling by mass spectrometer	65	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 353	proteomic profiling by mass spectrometer	65	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 353	proteomic profiling by mass spectrometer	65	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 353	proteomic profiling by mass spectrometer	65	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 353	proteomic profiling by mass spectrometer	65	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 353	proteomic profiling by mass spectrometer	65	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 353	proteomic profiling by mass spectrometer	65	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 353	proteomic profiling by mass spectrometer	65	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 353	proteomic profiling by mass spectrometer	65	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 354	proteomic profiling by mass spectrometer	66	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 354	proteomic profiling by mass spectrometer	66	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 354	proteomic profiling by mass spectrometer	66	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 354	proteomic profiling by mass spectrometer	66	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 354	proteomic profiling by mass spectrometer	66	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 354	proteomic profiling by mass spectrometer	66	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 354	proteomic profiling by mass spectrometer	66	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 354	proteomic profiling by mass spectrometer	66	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 354	proteomic profiling by mass spectrometer	66	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 354	proteomic profiling by mass spectrometer	66	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 355	proteomic profiling by mass spectrometer	67	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 355	proteomic profiling by mass spectrometer	67	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 355	proteomic profiling by mass spectrometer	67	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 355	proteomic profiling by mass spectrometer	67	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 355	proteomic profiling by mass spectrometer	67	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 355	proteomic profiling by mass spectrometer	67	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 355	proteomic profiling by mass spectrometer	67	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 355	proteomic profiling by mass spectrometer	67	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 355	proteomic profiling by mass spectrometer	67	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 355	proteomic profiling by mass spectrometer	67	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 356	proteomic profiling by mass spectrometer	68	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 356	proteomic profiling by mass spectrometer	68	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 356	proteomic profiling by mass spectrometer	68	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 356	proteomic profiling by mass spectrometer	68	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 356	proteomic profiling by mass spectrometer	68	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 356	proteomic profiling by mass spectrometer	68	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 356	proteomic profiling by mass spectrometer	68	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 356	proteomic profiling by mass spectrometer	68	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 356	proteomic profiling by mass spectrometer	68	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 356	proteomic profiling by mass spectrometer	68	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 357	proteomic profiling by mass spectrometer	69	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 357	proteomic profiling by mass spectrometer	69	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 357	proteomic profiling by mass spectrometer	69	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 357	proteomic profiling by mass spectrometer	69	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 357	proteomic profiling by mass spectrometer	69	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 357	proteomic profiling by mass spectrometer	69	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 357	proteomic profiling by mass spectrometer	69	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 357	proteomic profiling by mass spectrometer	69	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 357	proteomic profiling by mass spectrometer	69	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 357	proteomic profiling by mass spectrometer	69	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 358	proteomic profiling by mass spectrometer	70	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 358	proteomic profiling by mass spectrometer	70	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 358	proteomic profiling by mass spectrometer	70	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 358	proteomic profiling by mass spectrometer	70	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 358	proteomic profiling by mass spectrometer	70	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 358	proteomic profiling by mass spectrometer	70	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 358	proteomic profiling by mass spectrometer	70	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 358	proteomic profiling by mass spectrometer	70	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 358	proteomic profiling by mass spectrometer	70	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 358	proteomic profiling by mass spectrometer	70	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 359	proteomic profiling by mass spectrometer	71	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 359	proteomic profiling by mass spectrometer	71	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 359	proteomic profiling by mass spectrometer	71	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 359	proteomic profiling by mass spectrometer	71	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 359	proteomic profiling by mass spectrometer	71	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 359	proteomic profiling by mass spectrometer	71	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 359	proteomic profiling by mass spectrometer	71	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 359	proteomic profiling by mass spectrometer	71	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 359	proteomic profiling by mass spectrometer	71	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 359	proteomic profiling by mass spectrometer	71	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	run 360	proteomic profiling by mass spectrometer	72	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	run 360	proteomic profiling by mass spectrometer	72	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	run 360	proteomic profiling by mass spectrometer	72	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	run 360	proteomic profiling by mass spectrometer	72	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	run 360	proteomic profiling by mass spectrometer	72	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	run 360	proteomic profiling by mass spectrometer	72	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	run 360	proteomic profiling by mass spectrometer	72	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	run 360	proteomic profiling by mass spectrometer	72	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	run 360	proteomic profiling by mass spectrometer	72	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	run 360	proteomic profiling by mass spectrometer	72	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	tissue	control	control
